¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/4 ¤W¤È 09:37:32
²Ä 3883 ½g¦^À³
|
¼Æ¾Ú¨ì¨º¸Ì ¹Ú·Q¨ì¨º¸Ì èB¦V«e ¿v¹Ú½ñ¹ê ¬O§_Àò§Q ¹B®ð©~¦h ¦æµ½¿n¼w ®É¨Ó¹BÂà |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/4 ¤W¤È 08:43:32
²Ä 3882 ½g¦^À³
|
¥»¦¸¸Ñª¼ 400mg/600mg ESAI 50/75/90 ¡A¯uªº¥O¤HÅåÆv¡C
¤T´Áªº¥Dn«ü¼Ð¡A¶W¶VDupilumab¤T´Á«Ü¦h¡A«Ü¦h¡C 1.ESAI50 ASLAN004 87% vs dupilumab. 61% 1.ESAI75 ASLAN004 67% vs dupilumab 50% 2.ESAI90 ASLAN004 57% vs dupilumab 33% 3.¤é«á16¶gªºªvÀøIGA,0,1¤ñ²v ¦Û·|¾aªñESAI-90
¦¨¥\ÅçÃÒM0A¡A¤S¶W¶VÅQ¥DDupiluma ¼Ð·ÇÀøªkªºÀø®Ä¡C
¯uªº¦p¤½¥q¥»¦¸Á{§É结½× robust and differentiated safety and efficacy profile
¦bÁ{§É¼Æ¾Ú¤½§i¤¤¥Îrobust³oÓ¦rªí¥Ü¼Æ¾Ú«Ü¦³Àu¶Õ¡A«Ü¦³Ävª§¼ç¤O¡A¼Æ¾Ú±j¦Ó¦³¤O¡C
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
ASLAN004 400mg/600mgx¨C¶g¤@°w x8¶g vs Dupilumab ¨C¶g¤@°wx16¶g
(¤@).400mg/600mg QW(¨C¶g¤@°w/8¶g)
EASI-50 83%/100% EASI-75 67%/67% EASI-90 67%/33% IGA0/1 17%/33%(¥Dn«ü¼Ð)¡X¡X67%ªºESAI ,IGA 0.1 =17% , ¼Æ¾Úª½ªº©_©Ç¡AIGA0.1 ¤é«á¥²¤W¤Éªñ67%
(¤T)¹ï·Ó²ÕPlacebox8¶g
EASI-50 40% EASI-75 0% EASI-90 0% IGA0/1 0%(¥Dn«ü¼Ð)
¡X¡X¡X¡X¡X¡X Dupliumab 3´Á ¤¤-««×AD, 2ÓSOLO1/SOLO2 Á{§Éªº«ü¼Ð(2016¦~¤½¥¬)
(¤@).300 mg QW(¨C¶g¤@°w/16¶g)¡A°_©l¶q600mg
EASI-50 61%/61% EASI-75 52%/48% EASI-90 36%/30% IGA0/1 38%/31%(¥Dn«ü¼Ð)
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 25%/22% EASI-75 15%/12% EASI-90 8%/7% IGA0/1 10%/8%(¥Dn«ü¼Ð) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/4 ¤W¤È 08:20:36
²Ä 3881 ½g¦^À³
|
A robust and differentiated safety and efficacy profile
¦bÁ{§É¼Æ¾Ú¤½§i¤¤¥Îrobust³oÓ¦rªí¥Ü¼Æ¾Ú«Ü¦³Àu¶Õ¡A«Ü¦³Ävª§¼ç¤O¡A¼Æ¾Ú±j¦Ó¦³¤O¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/4 ¤W¤È 08:07:53
²Ä 3880 ½g¦^À³
|
¤Ñ©R¤j ¦~¤¤¤½§i¼Æ¾Ú¨Ì¾ÚÂå¾Çªø»¡ªk¬O¹êÅç²Õ¥[¹ï·Ó²Õ¬ù50¤H Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, commented: ¡§These data are very encouraging and provide a strong foundation to confidently advance our plans for the global Phase 2b study we intend to initiate later this year. A robust and differentiated safety and efficacy profile is emerging for ASLAN004 and we look forward to reporting the full, unblinded data from approximately 50 patients in mid-2021. We believe the interim data demonstrate ASLAN004¡¦s potential as a first-in-class therapeutic targeting the IL-13 receptor with a differentiated approach to treating atopic dermatitis.¡¨ Ó¤H»{¬°¬y¥¢ªº³¡¥÷¥i¥[¦¬¡Aì¨Ó¹êÅç³]p´N¬O50¤H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/4 ¤W¤È 06:53:48
²Ä 3879 ½g¦^À³
|
¥xÁÞ¤j¡A
´Á¥½¸Ñª¼
ASLAN004 600mg
¹ê»Ú组 24¤H
¹ï·Ó组 12¤H
¦Xp36¤H¡A
¤@¯ë>=30¤HªºÁ{§É¡A¤è²Å±`ºA¤À°tªº统p·N¸q¡C
²Ä¥|组±qì¥ý¡A18¤H¡A¼W¥[6¤H¡A¨ì24¤H¡A ¨ä¤¤ªºì¦]¤§¤@¡A¥i¯à´N¬O¦p¤W¦Ò¼{¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/4 ¤W¤È 06:39:40
²Ä 3878 ½g¦^À³
|
¥¼¨Ó2bÁ{§É³]p °ª¾¯¶q400mg/600mgx2/4¶g¤@°wx16¶g¡A¥i¯à©Ô¶}Dupilumab ©úÅ㪺Àø®Ä®t²§¡A¬O¥«³õÄv¤Oªº®i²{¡C
MOA¡A¤w³QASLAN004ÅçÃÒ¤F¡A¤j®a¥i©ñ¤ß¡C
³Ì¨ÎADÀøªk¯uªº¦p¤½¥q©ÒºÙ¡A谮¤O¹ê¨¬¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/4 ¤W¤È 06:22:49
²Ä 3877 ½g¦^À³
|
¥xÁÞ¤j¡A
ASLAN004 200mg 组ªºESAI-75ªº°´T¤´¦³50%¡A¤£®z©óDupilumab ¤T´Á资®Æªº²Ä8¶g¡A ¦Ó¸Ó²ÕªºIGA 0.1¡A16¶g«á¡A¹Fdupilumab ªº¤ô·Ç¡A¥i¯à¦³¶W¹L80%ªº¾÷²v¡C
¥u¬OASLAN004 400mg/600mg ¬°«÷¥|¶g¤@°w¡A±Ä°ª¾¯¶q¡A¦b¦w¥þ¡A§C°Æ§@¥Îªºª¬ªp¤U¡Aµo挥§Ö³t¥B°ª¤ñ²vªºESLAN-50/75/90¡C
Dupilumab ¦]¦³结½¤ª¢¤Î¨¤½¤ª¢ªº°Æ§@¥Î¡A¤é«án¥Î°ª¾¯¶q¥i¯à¤£©ö¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/3 ¤U¤È 10:39:33
²Ä 3876 ½g¦^À³
|
è3.85¶R¤F5000ªÑ ²{¦b¦¨¥»°¨ì4¶ô¦h¡A¦@25000ªÑ µ¥¤¤ë¦A¦^¨ÓÅo ·à¤l¥[ªo¡A¤j®a¥[ªo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/3 ¤U¤È 07:31:10
²Ä 3875 ½g¦^À³
|
©ú¤Ñ¤j±zªGµM¤]¬O¦æ®a §Ú¤]²ßºD¶R¶Â¤£¶R¬õ §Ú¥Ø«e¬O±¾3.9¶R5000ªÑ ¸ò±z¹w¦ô±µªñ 4¤¸µu½u¬OÓÀ£¤O¡A¦ý¥¼¨Ó±NÅܦ¨¤ä¼µ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/3 ¤U¤È 07:18:49
²Ä 3874 ½g¦^À³
|
to «Ó¤j «Øijn¥[½Xªº¸Ü´N³{¶Â¥[½X,¤£n¨£¬õ¥[½X,¬üªÑº¦¶^´T«Ü¤j«Ü®e©ö¨ü¶Ë,µM«á¨C¤Ñª½±µ¤U¹w¬ù³æ-10%¶R¶i,¨Ò¦p¤µ¤Ñ§A´N±¾3.88¶R¤J,¨C¤Ñ«ö¦¬½L»ù-10%¹w¬ù³æ¶R¤J,n¦³@¤ß¤£nļ¶i,¶R¨ì§AªºªÑ¼Æº¡¨¬ÂI¬°¤î ! ¦ýnª`·N¤âÄò¶O¸ò¤U³æª÷ÃB¤ñ¨Ò¬O§_¦Eºâ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 07:14:24
²Ä 3873 ½g¦^À³
|
2026¦~3¤ë, ASLAN003 MS,10»õ¬ü¤¸ªº³Ì°ª¾P°â,2B §¹¦¨, ¤@°_¤ÏÀ³,³Ì°ª25»õ¬ü¤¸ªº¥«È.
ASLAN004 150»õ¬ü¤¸+ASLAN003 25»õ¬ü¤¸=175»õ¬ü¤¸----
175»õ¬ü¤¸/115,000¤dªÑ=150 ¬ü¤¸/ADR
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 07:02:00
²Ä 3872 ½g¦^À³
|
ASLAN004 2026¦~3¤ë¨ú±oADÃĵý,¦ô150»õ¬ü¤¸/115,000¤dªÑ ,130¬ü¤¸ /ADR
AD 3´Á »Ý4»õ¬ü¤¸ ý³Ý¤]¦b¤T´ÁÁ{§É¤¤ .¶·3»õ¬ü¤¸ ASLAN003 MS ,¦ô2´Á§¹¦¨ ¶·1»õ¬ü¤¸
¥¼¨Ó¶·8»õ¬ü¤¸ªº²{ª÷,
°²³]«D¬ü±ÂÅv¦¨¥\ ,2b AD ¦¨¥\¸Ñª¼, 2022¦~12¤ë ¶Ò¸ê3»õ¬ü¤¸,+±ÂÅv2»õ²{ª÷¤J¤f³U 20¤¸¼W¸ê*15,000¤dªÑ ADR
2023¦~10¤ë¶}©l3´ÁAD~+18Ó¤ë2025¦~3¤ë¸Ñª¼, 2026¦~3¤ë¨ú±oÃĵý
2023¦~ ý³Ý ¤T´Á2024¦~¶}©l,¦A¶Ò3»õ+ASLAN--3 MS 2B 1»õ¬ü¤¸,,
30¤¸*15,000¤dªÑ ADR, ªÑ¥»100,000 ¤dªÑ
2025¦~ ¾P°â¹Î¶¤¶Ò¸ê7.5¬ü¤¸ 50*15,000¤dªÑADR
ªÑ¥»:115,000 ¤dªÑ,¥«È60»õ¬ü¤¸
2026¦~ 3¤ë ¨úADÃĵý,2026¦~6¤ë¥«È150»õ¬ü¤¸
150»õ¬ü¤¸/115,000¤dªÑ ,130¬ü¤¸ ADR
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/3 ¤U¤È 06:56:38
²Ä 3871 ½g¦^À³
|
¦pªG¦³¥|¤¸¥H¤U§Ú·|·Q¥[½X ÁöµM¼W¸ê¹ïµu½uªÑ»ù¦³À£ ¦ý¥t¤@¤è±¤½¥qªº¸êª÷¤]§ó¥R¨¬ ¨Ã¤£¥þµM¬OÃa®ø®§ 쥻ÁÙ¦bµS¿Ý¬O§_¥[½X¡A¦pªG¯uªº¶^¤U¨Óµ´¹ï¤£·|¿ðºÃ ¤Ñ©R¤jªº25000ªÑ°]´I¦Û¥Ñ½×¤Ó§l¤Þ¤H¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/3 ¤U¤È 06:37:43
²Ä 3870 ½g¦^À³
|
¤Ñ©R¤j
§ÚÓ¤H¬O°¾¥¿¦V¸ÑŪ : 6000¸U¬üª÷¤½§i¨ì¦¬Áʵuµu´X¤Ñ´N§¹¦¨,ªí¥Ü¹ï¼Æ¾Ú¬O«Ü¦³«H¤ß¤~·|¯{¿ú§ë¸ê ! ±µ¤U¨Ó¼vÅTªÑ»ùªºÂIÀ³¸Ó¬O 1.ASLAN003¤½§iÁ{§É®É¾÷ÂI 2.¦A¨Ó´N¬O 5/31ªº¤jÀ¸ §¹¾ã¼Æ¾Ú¸Ñª¼ ³£µ¥¤F´X¦~¤F...¦bµ¹¥L¥b¦~®É¶¡¤]¤£ºâ±Ë !
©Ò¥H§Æ±æ³o¦¸¥i¥H¼µ¦bUSD 4¤§¤W¡]§O¹³¤W¦¸2.5¼W¸ê§¹²¦¤§«á¤@¸ô¤S¶^¨ì1.5¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 06:30:42
²Ä 3869 ½g¦^À³
|
¨È·à§É³Ì¥i¯à³Q¨ÖÁʮɾ÷,¦b¸Ñª¼2b ¦¨¥\«áªº²Ä12Ó¤ë,¬ù¦b2023¦~©³.
½Í§P»Ý1¦~ªº®É¶¡.
®Ú¾Ú©³¤U®×¥ó¹w¦ôªº®É¶¡
𠃊ebrikizumab «Å¥¬ 2b¸Ñª¼¦¨¥\ªº¤é´Á¦b2019¦~3¤ë18¤é
¼Ú¬w±ÂÅv2019¦~2¤ë 2019¦~10¤ë¶}©l¤T´ÁÁ{§É 2019¦~12¤ë §¨Ó«Å¥¬¦¬ÁÊ.
2020/¤¸¤ë ,§¨Ó¨ÖÁÊDermira ¤½¥q/Lebrikizumab
§é²{»ùÈ 29»õ¬ü¤¸.
11»õ¬ü¤¸²{ª÷+ ¤ä¥Iù¤óROCHE Lebrikizumab¥þ²yAD¶}µoÅv,°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%.
§é²{Ȧô 29»õ¬ü¤¸, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 05:44:15
²Ä 3868 ½g¦^À³
|
finance.yahoo.com/quote/REGN/ Regan ¤ÏÀ³dupilumab À禬¹w´ú¦@3¦¸
1.2014¦~6¤ë dupilumab «Å¥¬¸Ñª¼2b ¦¨¥\ ¥Ñ 2014¦~9¤ë¨ú±oBTD(¬ð¯}©ÊÀøªk)
ªÑ»ù¥Ñ 300¬ü¤¸¤jº¦¦Ü2015¦~7¤ë 550¬ü¤¸,¥«È¼W¥[250»õ¤¸¬ü¤¸,¨ä¤¤«Ü¤j³¡¤À¦b¤ÏÀ³Dupilumab ¥¼¨ÓªºÀ禬 ·í®É¤À§é®v¦ô50»õ¬ü¤¸ªº¾P°â. ¥t¤@Óì¦]¤ÏÀ³¥t¤@Ó¤jÃĪvÀø¶À¯Z³¡¯fÅܪº°w¾¯.
2. 2017¦~ 3¤ë ¨ú±oAD Ãĵý ,¤jº¦¤@¬q 367~491 , ¤jº¦125»õ¬ü¤¸
3.2019¦~12¤ë CEO´£°ª¾P°â¹w´ú¨ì110»õ¬ü¤¸ªºdupilumab
277~619 , ¤jº¦340»õ¬ü¤¸ ¨ä¤¤Dupilumab ¦]¯À¦û¤@¤j³¡¤À¡A¥i¯à150»õ¬ü¤¸ªº¥«È¤ÏÀ³.
¡X¡X¡X¡X¡X¡X¡X¡X¡X ¥t¥~¤é¥»²Ä¤@¤T¦@¡AADC ¨â´Ú·sÃıÂÅvµ¹^°ê AZ, 119»õ¬ü¤¸¥ª¥k¡A¤ÏÀ³ªº¥«È®t¤£¦h2.5x119»õ¬ü¤¸ªºªÑ»ù¡A
¡X¡X¡X¡X
©ú¤Ñ¤j,
5¤ë31¤én¸Ñª¼600mg 24¤H¡A¡Ï¤§«e 6¡Ï6 ,¦@36¤H¡A³oµ´¹ï¬O¤j¨Æ¡C
ªÑ»ù¤£·|¦A¤j¶^¤F¡A¦³¤j¶^¬O¤j®aªº«Øܪø§ëªº¦n®É¾÷¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 05:19:05
²Ä 3867 ½g¦^À³
|
¤T´Á¦¨¥\¨ú±oÃĵý«áªº3~4 Ӥ뤺¡A¥«³õ·|¦Û°Ê¤ÏÀ³¤À§é®v©Ò¦ôªº³Ì°ªÀç·~ÃB.
°²³]¥«³õ»{¦P60»õ¬ü¤¸ªº³Ì°ªÀç·~ÃB. 60»õx3¿ =180»õ¬ü¤¸ ¡X¡X¡XªÑ»ù¥«»ù
¦©°£À³¥ICSLªº¦¨¥»¬ù30»õ¬ü¤¸¡C
180-30=150»õ¬ü¤¸.
¬ü°ê°Ï¶·¤½¥q¦Û¦æ销°â¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/3 ¤U¤È 04:56:37
²Ä 3866 ½g¦^À³
|
¤j®an¦³¤ß²z·Ç³Æªø´Á§Ü¾Ô¤F,¦³¤@®a¤½¥qADAP¥h¦~6¤ë¤]¬O¼W¸ê»ù11¶ô, ·í®ÉªÑ»ù11.6 ,¼W¸ê§¹²¦«á¤@¸ô¤U¶^¨ì²{¦bªº6¶ô¿ú ,§Æ±æASLN ¥i¥H¥´¯}¼W¸êªÑ»ù´N¤U¶^ªºÅ]©G !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¯È¤W´I¶Q10134993 |
µoªí®É¶¡:2021/3/3 ¤U¤È 04:30:39
²Ä 3865 ½g¦^À³
|
¤Ñ©R¥S ½Ð°Ý §A©Ò»¡ªº¡¨°µ¨ì®³Ãĵý150»õ¬ü¤¸»ùȶ]¤£±¼¡¨
³o¬O«ü³Q¨ÖÁÊ»ùȶܡH
©¡®ÉªÑ¥»¤j¬ù·|¬O¦h¤Ö©O¡H
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 03:54:00
²Ä 3864 ½g¦^À³
|
Piper Sandler ¬O¥»¦¸¦¨¾P°Ó¤§¤@
¥t¤@®a¦¨¾P°ÓH.C. Wainwright & Co. ,¤]±`¥XASLN ¥Ø¼Ð»ù³ø§i
¨ì«e¬°¤î¯u·Ç.
Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering
¤U¦¸¥Ø¼ÐPiper Sandler »ù©w¦b10¬ü¤¸.
¦ó®É¯à¹ê²{? ¤£ª¾¹D
Piper Sandler±NAslan Pharmaªº»ù®æ¥Ø¼Ð´£°ª¦ÜµóÀY³Ì°ª
2021¦~3¤ë1¤é¡A¤W¤È11:01 ETASLAN Pharmaceuticals Limited¡]ASLN¡^¡A§@ªÌ¡GDulan Lokuwithana¡ASA·s»D½s¿è Piper Sandler¦b¯SÀ³©Ê¥Öª¢ªº1´Á¬ã¨s¤¤«Å¥¬¨ä³æ§J¶©§ÜÅéASLAN004ªº¤¤´Á¤¤´Áµ²ªG¬°¶§©Ê«á¡A±NASLAN»sÃÄ¡]ASLN + 22.3¢H¡^ªº»ù®æ¥Ø¼Ð±q¨CªÑ6.00¬ü¤¸¤W½Õ¦ÜµØº¸µó°ªÂI¡A¦Ü10.00¬ü¤¸¡C µM¦Ó¡A¤ÀªR®v·R¼wµØ¡PA¡P©Z¯Á¤Ò¡]Edward A. Tenthoff¡^¤Î¨ä¹Î¶¤±Nµû¯Åºû«ù¦b¼W«ù¤£ÅÜ¡A¦Ó·sªº»ù®æ¥Ø¼Ð·N¨ýµÛ¸û¤W¤@¥æ©ö¤é¤Wº¦¬ù125.7¢H¡C ÀHµÛ²Ä¥|Ó¡]ÂX®i¡^¶¤¦C¡]600²@§J¡^ªº¤J¾Ç¥Ó½Ð¡A¸Ó¤½¥qª`·N¨ì¦³¥i¯à¦b2021¦~¤¤´Á«Å¥¬¸Ó¬ã¨sªº§¹¾ã¡A«Dª¼¼Æ¾Ú¡C ¤ÀªR®v¹w´ú¡A¦b400²@§J©M600²@§J¥Ö¤Uª`®g¯SÀ³©Ê¥Öª¢®É¡AASLAN004±N¦b2H 2021¦~2b´Á¶}©l¬ã¨s¡A¤ÀªR®vÁÙ¹wpAslan³Ì²×±N¦b¨ä¥L¹L±Ó©Ê¯e¯f¤¤µû¦ôASLAN004¡C 1¤ë¥÷¡A¸Ó¤½¥q«Å¥¬¡A¼Æ¾ÚºÊ±±©eû·|¬°¸Ó¸ÕÅ窺³Ì«áÂX®i¶¤¦C¤¤±wªÌ¤J²Õªº¶}©l¶}¤Fºñ¿O¡C
Aslan Pharma price target raised to a Street-high at Piper Sandler
Mar. 01, 2021 11:01 AM ETASLAN Pharmaceuticals Limited (ASLN)By: Dulan Lokuwithana, SA News Editor Piper Sandler has upped the price target of ASLAN Pharmaceuticals (ASLN +22.3%) to a Wall Street-high of $10.00 from $6.00 per share after the company announced positive interim results for its monoclonal antibody ASLAN004 in a Phase 1 study in atopic dermatitis. The analyst Edward A. Tenthoff and the team have however kept the rating unchanged at overweight, and the new price target implies ~125.7% upside to the previous close. With enrollment for the fourth (expansion) cohort (600mg) ongoing, the firm notes a possible announcement of full, unblinded data from the study in mid-2021. Predicting the initiation of a Phase 2b study in 2H 2021 for ASLAN004 in atopic dermatitis with 400mg and 600mg subcutaneous injections, the analysts also expect Aslan to ultimately evaluate ASLAN004 in other allergic conditions. In January, the company announced that the Data Monitoring Committee greenlighted the start of patient enrollment for the final expansion cohort of the trial. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 03:43:59
²Ä 3863 ½g¦^À³
|
4¬ü¤¸ªº©w»ù°ò¦¬O5¬ü¤¸
¥«»ù¥´80%
5*80%=4¬ü¤¸
15,000¤dªÑ ADR +15%*15,000¤dªÑ ¤âÄò¶OADR, (¥i¯à¥]¾P¨î?) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/3 ¤U¤È 03:37:59
²Ä 3862 ½g¦^À³
|
ì¨Ó¸¤H¤jÁÙ¦b 4¤¸¼W¸ê¦³ÂI¤Ó«æ¡A»ù¦ìq¤Ó§C ³o¼Ëµu½uªÑ»ù¤S·|¦³À£¤O¤F ¦pªG§Ún¥[½X§Ú¤]·|·Q¶R4¤¸¥H¤U |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 03:33:11
²Ä 3861 ½g¦^À³
|
70,000ªÑADR ªÑ¥», §t¤º³¡¼úÀy»{ªÑ¬ù7000¤dªÑADR,.
¥¼¨Ó¬ù¥iÄw1400~2500¸U¬ü¤¸¥H¤W?
¦³¨Ç¦b3¦~«e¤v©w»ù¦b7¬ü¤¸,©|¥¼»{ÁÊ,
¦~ªì·s¼W4000¤dªÑ,©w»ù2¬ü¤¸¥ª¥k,2022¦~«á10¦~¤Àµo¤º³¡û¤u) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 02:55:00
²Ä 3860 ½g¦^À³
|
¾ãӶҸ꧹¦h¥X1»õ¬ü¤¸²{ª÷.
¦ý¼W¥[75%ªÑ¥».
¥xÆWªº¥Í§Þ¤½¥q¸û¼F®`,¦ý®`W§ë¸êªÑªF,¤@¦¸©Ô¨ì¨ú±oÃĵýªºªÑ»ù,«á±¶RªºnÂê¦n¦h¦~¤~¯àÀò§Q.
¬ü°ê¥«³õ¤ñ¸û¥Ã,¦ý¸Ó¦³ªº»ùÈ,¤@©w¤ÏÀ³.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 02:37:25
²Ä 3859 ½g¦^À³
|
¼W¸ê§¹ªÑ¥»¬ù70,000¤dªÑADR ,¥«È¬ù3»õ¬ü¤¸ªº¤p¤½¥q.
¥Ø«e³Q¨ÖÁÊ»ù 35»õ¬ü¤¸, 50¬ü¤¸ªº´Á±æÈ.
2022¦~©³¦X²z³Q¨ÖÁÊ»ùȱN¨ì42»õ¬ü¤¸.
°µ¨ì®³Ãĵý150»õ¬ü¤¸»ùȶ]¤£±¼.
ªÑ»ù³Ì¤j¤ÏÀ³¦b®³¨ìÃĵý«á3~6Ó¤ë,
¦A¨Ó¬Ý¹ê»Ú¾P°â¯à§_¶W¶V60»õ¬ü¤¸ªº¹w´Á,¤~·|¤@¸ô¥h.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 02:20:33
²Ä 3858 ½g¦^À³
|
¦³§ä¤j¸}»{ÁÊ¡AÄw½X¤ñ¸û¦w©w¡C
·s»D½Z ASLAN»sÃīŧG¤½¶}µo°â¬ü°ê¦s°U¾ÌÃÒªº»ù®æ ·s¥[©Y¡A2021¦~3¤ë3¤é¡V ASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¬O¤@®a±Mª`©óÁ{§É¶¥¬q§K¬Ì¾Çªº¥Íª«»sÃĤ½¥q¡AP¤O©ó¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A ¤µ¤Ñ«Å¥¬©w»ùµo¦æ1500¸UªÑ¬ü°ê¦s°UªÑ¥÷¡]¡§ ADSs¡¨¡^ ¡^¥Nªí75,000,000ªÑ´¶³qªÑ¡A¥H¨CªÑ¬ü°ê¦s°UªÑ¥÷$ 4.00ªº»ù®æµo¦æ¡C
¦¹¦¸µo¦æªºÁ`¦¬¯q¹wp¬°6000¸U¬ü¤¸¡A¨ä¤¤¤£¥]¬AASLANÀ³¥Iªº©Ó¾P§é¦©©M¦þª÷¥H¤Î¦ôpªºµo¦æ¶O¥Î¡C®Ú¾ÚºD¨Ò¦¨¥æ±ø¥ó¡A¹wpµo¦æ±N©ó2021¦~3¤ë5¤é¥ª¥kµ²§ô¡C¦¹¥~¡AASLANÁٱ¤©©Ó¾P°Ó30¤Ñªº¿ï¾ÜÅv¡A¨Ï¨ä¥i¥H¥H¤½¶}µo¦æ»ùÁʶR³Ì¦h2,250,000ªÑÃB¥~ªºADS¡A´î¥h©Ó¾P§é¦©©M¦þª÷¡C
ASLAN¹wp±N§Q¥Î¦¹¦¸µo¦æªº²b¦¬¯q¤Î¨ä²{¦³²{ª÷©M²{ª÷µ¥»ùª«¡A¥Dn¥Î©ó¸ê§U¨äp¹º¤¤ªºASLAN004 2b´Á¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢±wªÌ¾¯¶q½d³ò¸ÕÅç¡C ASLANÁÙ¥²¶·ÀvÁÙ¥»¦¸µo¦æªº²b¦¬¯q¤¤ªº225¸U¬ü¤¸¥»ª÷¥H¤ÎÀ³©ó2019¦~10¤ë©M2019¦~11¤ëñqªº¶U´Ú¦w±Æ¤UªºÀ³p©M¥¼¥I§Q®§¡C©Ò±o´Ú¶µ²bÃBªº¨ä¾l³¡¤À¡]¦p¦³¡^±N¥Î©ó¸ê§U·sªº©M¨ä¥L¥¿¦b¶i¦æªº¬ãµo¬¡°Ê¡AÀç¹B¸êª÷©M¨ä¥L¤@¯ë¤½¥q¥Î³~¡C Jefferies LLC©MPiper Sandler¡®Co.¾á¥ô¸Ó²£«~ªºÁp®u½ãïºÞ²z¤H¡C H.C. Wainwright¡®Co.¾á¥ô¦¹¦¸µo¦æªºº®u¸g²z
PRESS RELEASE ASLAN PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES Singapore, 3 March 2021 ¡V ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the pricing of an underwritten public offering of 15,000,000 American Depositary Shares (¡§ADSs¡¨) representing 75,000,000 ordinary shares at a price to the public of $4.00 per ADS. The gross proceeds from this offering are expected to be $60.0 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by ASLAN. The offering is expected to close on or about March 5, 2021, subject to customary closing conditions. In addition, ASLAN has granted the underwriters a 30-day option to purchase up to 2,250,000 additional ADSs at the public offering price, less the underwriting discounts and commissions. ASLAN expects to use the net proceeds from the offering, together with its existing cash and cash equivalents, primarily to fund its planned ASLAN004 Phase 2b dose-range-finding trial in moderate-to- severe atopic dermatitis patients. ASLAN is also required to repay $2.25 million of principal amount plus accrued and unpaid interest under its loan facilities entered into in October and November 2019 with the net proceeds from this offering. The remainder of the net proceeds, if any, will be used to fund new and other ongoing research and development activities, working capital and other general corporate purposes. Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2021/3/3 ¤U¤È 01:59:42
²Ä 3857 ½g¦^À³
|
¤j®a¦n¤[¤£¨£! èè·s»D¥X¨Ó¤F¡A³o¦¸¼W¸êq»ù¬O1ªÑ4¤¸¡A§A¨S¬Ý¿ù¡A¤S¬O¤@Ó¤ñ²{»ù§Cªº»ù®æ¡A§Ú·Q¤µ¤Ñ½L«e¥æ©ö¤S·|¶^¨ì4¤¸¥ª¥k§a¡AÄ~¤W¦¸ª£¨ì8¶ô¦h¡A¤½¥qq»ù2.5¡A³o¦¸¤ñ¸û¦n±q6¶ô¦h¨º¤Ñ´Nµo¥¬¼W¸ê¤F¡AªÑ»ù¤]¤w¸g¦^¶^¨ì4.3X¡A¥u¬O¸Ñª¼¦¨¥\³oÓ§Q¦h¡A´N³Q¼W¸êq»ù4¤¸µ¹¦Y±¼¤F¡A¤j®anÄ~Äòµ¥«Ý¤F! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 01:22:06
²Ä 3856 ½g¦^À³
|
------------------------------ 2022¦~©³,¤½¶}¶Ò¸ê3.1»õ¬ü¤¸/¶Ò¸ê´Á±æ»ù¦b20¬ü¤¸/¨CªÑADR.
20*62,000¤dªÑ*25%=3.1»õ¬ü¤¸.
¦Xp¶Ò¸ê 2.9»õ¬ü¤¸±ÂÅv+3.1»õ¬ü¤¸¤½¶}¥«³õ¶Ò¸ê=6»õ¬ü¤¸
***YªÑ»ùº¦¨ì30¬ü¤¸,«h¥i¦h¶Ò1.55»õ¬ü¤¸
°µ¤T´Á®É¶·¤ä¥ICSL 3000¸U¬ü¤¸ ¦V·s¥[©Y¬F©²¶U´Ú¬ù1500¸U¬ü¤¸,¤]¥i¯à¶·ÁÙ.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 12:58:00
²Ä 3855 ½g¦^À³
|
2022¦~©³¹w¦ô±ÂÅv
«D¬ü°Ï¾P°â±ÂÅv¹w¦ô,¦û30% À禬*60»õ¬ü¤¸ASLAN004 ³Ì°ª¾P°â=18»õ¬ü¤¸
4»õñ¬ùª÷(2.9»õ¬ü¤¸²{ª÷+1.1»õ¬ü¤¸ùµ{ª÷)+50% ¾P°â¤À¼í
¬ù11»õ¬ü¤¸ªº§é²{»ùÈ.(37*30%=11»õ¬ü¤¸)
°Ñ¦Ò¦p¤U
2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¤À¼í50% ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤U¤È 12:41:21
²Ä 3854 ½g¦^À³
|
¤U¥b¦~¤½¥qªºp¹º ASLAN004 2b AD (2022¦~©³§¹¦¨)*250¤H ASLAN004 2a ý³Ý(24¶gªvÀø,2022¦~©³§¹¦¨) *90¤H ASLAN003 2a MS(24¶gªvÀø,2022¦~©³§¹¦¨)* 90 ¤H
2022¦~¤U¥b¦~, ¬°°µ¤T´ÁÁ{§Éªº¸êª÷, ¥t¤@½üªº¶Ò¸êp¹º±N°_°Ê
«D¬ü°Ïªº±ÂÅv,¥i¯à¦b2b AD¸Ñª¼«e,´N±ÂÅv.
¥H¤W for ªø§ëªº¤j¤jÌ
2022¦~©³ ASLAN004 ²{ª÷¨ÖÁÊ»ù¬ù34+3(§é²{È)=37»õ¬ü¤¸ ASLAN004 ²{ª÷¨ÖÁÊ»ù¬ù5»õ¬ü¤¸ ¦Xp42»õ¬ü¤¸
62,000¤dªÑ*1.25 ¶Ò¸ê=77,500 ¤dªÑ ADR
42»õ¬ü¤¸/77,500 ¤dªÑ=54 ¬ü¤¸/ADR ¼ç¦b³Q¨ÖÁÊ»ùÈ.
«¦ù©ñ¨ì¤½¥q³Q¨ÖÁʩΨú±oÃĵý, ¬°¥Ø«e¹w´Á³Ì°ªªºªø´Á§ë¸ê»ùÈ.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/3 ¤W¤È 11:51:04
²Ä 3853 ½g¦^À³
|
·PÁ¤ѩR©M¥xÁÞ¨â¦ì¤j¤jºë±mªº´£¨Ñ¦U¶µ¼Æ¾Ú½×ÂI Åý¤p§Ì¹êµÛÀò¯q¨}¦h ·à¤l¼Æ¾Ú¤½¥¬«á¡A³o¨â¤ÑªÑ»ù¨ü¨ì°±§Q½æÀ£¥´¤U¨Ó §Ö¦^¨ì¤W§«ô¨ºÓ§ë¸ê¾÷ºc1800¸U¬ü¤¸ªº¨p¶Ò»ù¤F ·Pı´N¬OÓ«Ü»¤¤Hªº¥[½XÂI
¤p§Ì·Q½Ð±Ðª©¤ÍÌ ¤j®a¦p¦¹¬Ý¦n·à¤l¡A·|·Q¦b¥Ø«e³oӮɾ÷ÂI¥[½X·à¤l¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤W¤È 11:22:24
²Ä 3852 ½g¦^À³
|
¥xÁÞ¤j¡A ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
400/600mg, ¦b²Ä¥|¶g¥§¡ESAl°´T¬Ò¶W¹L50%
¤]³\ ¥¼¨Ó³]p«e¤T°w¡A¨C¶g¤@°w¡A¤§«á4¶g¤@°w¡A 16¶g¦@7°w¡A¤§¥i¯à³]p¡C
Àø®Ä©Ô¥X®t¶Z¡Aq»ùµL须¥´§é¡AÁÙ¥i¶W¹LDupilunab10-20%ªºq»ù¡C ¤§¤U¥ÎASLAN004¡A¤´¦³¸gÀÙÀu¶Õ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/3 ¤W¤È 11:10:20
²Ä 3851 ½g¦^À³
|
¤Ñ©R¤j ¹ï·Ó²Õ°ò·Ç½uMean ESAI score ¬O33.9 ¤U°´T«×42% (33.9x0.58= 19.66
¹êÅç²Õ600mg°ò·Ç½u Mean ESAI score ¬O32.5 ¤U°´T«×76% (32.5x 0.24 = 7.8 ) 19.66/7.8= ¦n2.52 ¿ ¹êÅç²Õ400mg°ò·Ç½u Mean ESAI score ¬O30.9 ¤U°´T«×74% (30.9x 0.26 = 8.034) 19.66/8.034= ¦n2.45¿
Æ[¹î¦w¥þ©Ê@¨ü©Ê , EASI-50 EASI-75 EASI-90 , IGA 0/1 »P % change in pruritis NRS µ¥¥ÎÃĵ²ªG ¤ñ¸û«n , µ¥Æ[¹î¤H¼Æ¦h¤@ÂI, Æ[¹î®É¶¡¤[¤@ÂI ¼Æ¾Ú´N·|»¡¸Ü, §ó¦óªp³o¦¸´Á¤¤¼Æ¾Ú¥iµû¦ô¥u¦³18¤H ( ¹ï³o²Õ5¤H ¹êÅç²Õ13¤H ) 200mg ®ÄªG¤£©úÅã, ¥¼¨Ó¤GB Á{§É¸ÕÅç²q¤½¥q·|¥H400mg ©Î 600mg ¬°¥D ( ®ÄªG©ú½T)
²×©ó·Q³q¤½¥q¬°¤°»ò ±Ú¸sÂX¼Wn¦VºÊºÞ³æ¦ì¥Ó½Ð18¤H(12/6) 600mg ¨ÃÀò±o®Öã ¥H¥[³tÁ{§É®Éµ{ ( À³¸Ó¬ãµo¹Î¶¤ , ±M®aÅU°Ý¦³µû¦ôASLAN 004 ¦b²§¦ì©Ê¥Ö½§ª¢¦³·¥¤jµo®i¼ç¤O)
¥H¤WÓ¤H¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤W¤È 11:02:49
²Ä 3850 ½g¦^À³
|
Dupilumab ¤w«DASLAN004¦P级¡C
ASLAN004 600mg ¡A©Ô¥X¥i¯à²Îp¤Wªº©úÅã®t²§¡C
ESAI-50 ¡A¥ÎDupilumab ¦³39%µL¤ÏÀ³¡C
´Á«ÝASLAN004¡A¥¼¨ÓªºÅç§É¤´¦³87%¹F¨ìESAI-50ªº¤ô·Ç¡C ¤SµLDupilumabªºµ²½¤¥²¡C ¦P¼Ë»ù®æ¤U¡A«OÀI¤½¥q¤@©w¥ý±ÆASLAN004¡C ¦]¬°Dupilumab ¦h®ö费26%(87%-61%)¡AªºµL¤ÏÀ³16¶gªºªvÀø费¥Î¡C
¤j®aªø§ëªÌ¡An©êºò¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/3/3 ¤W¤È 10:50:08
²Ä 3849 ½g¦^À³
|
ª¯ª¯Á`¬O¶]¨Ó¶]¥h¡A¥D¤H©¹¥Ø¼Ð«e¶i´N¦n... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/3 ¤W¤È 10:32:00
²Ä 3848 ½g¦^À³
|
¬Q¤éº¦´T¤w¸g¥þ³¡¦^¦R,±µ¤U¨ÓÁÙ¬O·|¤j´T«×Àú¾ã²z¤j®an§¤Ã¤F ¤£n³Q¥ÏÃâ ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤W¤È 08:07:54
²Ä 3847 ½g¦^À³
|
Y°µ¤@¤p«¬70:70¤HªºÁ{§É¹êÅç ASLAN004 ±N§¹³ÓDUPILUMAB ,
¦bESAI-50/ESAI-75 «ü¼Ð¤W,¹F²Îp¤Wªº©úÅã®t²§.
ASLAN004 400mg/600mg VS DUPILUMAB ¤T´Á/300*16¶g/¨C¶g¤@°w
1.ESAI-50 ASLAN004 87% VS 61% N=30:30 ,P=0.021 ,©úÅã²Îp¤Wªº®t²§ 2.ESAI-75 ASLAN004 67% VS 50% N=70:70 ,P=0.041 ,©úÅã²Îp¤Wªº®t²§
¦A¨Óµ¥5¤ë31¤éªº600MG, ¹êÅç²Õ22¤H+¹ï·Ó²Õ12¤H,§¹¾ã¸Ñª¼³ø§i. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤W¤È 07:20:07
²Ä 3846 ½g¦^À³
|
¥xÁÞ¤j¡A ¤@¡BESAI-50³oÓ«ü¼Ð«D±`«n¡C
¯à¹FESAI-50ªÌ¡A¥Nªí¦³¤ÏÀ³¡C Dupilumab¦³30¦h%¡A¹F¤£¨ì¡A«OÀI¤½¥q¡A¤£¦A¤ä¥I¡A16¶g«áªº¶O¥Î¡A¥xÆW¡A^°ê¥ç¬O¡C
¥t¥~ASLAN004 600mg组 ¥§¡¤U°¦Ü50% ªº®É¶¡³Ì§Ö¡A¤ñ²v°ª100%(3/3)¡A400mg组83%(5/6)¡A16¶g«áÄ~Äò¥Î¨ì ¤@¦~ªº¤ñ¨Ò±N¤ñdupiluma 61%¥ª¥k¼W¥[«D±`¦h . ¬OASLAN004 «¤j§Q¦h¡A¤ñDupilumaÀ禬°ª15-20%ªº谮¤O¡C
¤G¡BESAI-75 ¬O2´Á¤Î3´ÁÁ{§Éªº¥Dn«ü¼Ð¡C
¥»¦¸ASLAN004-400mg/600mg组 67% VS¹ï·Ó组0%
Dupilumab ¤T´Á¨C¶g¤@°wx16¶g¡A ESAI-75 ¬O52%/48%¡C ASLAN004 8 ¶gªvÀø¡A§¹³ÓDupilumab¡A16¶gx300mgªvÀø 67%/50%=34%¡AÀu©óDupilumab ¡Ñ¡Ñ¡Ñ¡Ñ ¥»¦¸ASLAN004°ò½u¼Æ¾Ú¡A¬O¬Û·í±µªñDupilumab¤T´Á°ò½u¼Æ¾Ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/3 ¤W¤È 06:23:01
²Ä 3845 ½g¦^À³
|
¥xÁÞ¤j¡A
½Ð°Ý¥»¦¸¸Ñª¼ªºASLAN004¹ï·Ó组¡A ¥§¡ESAI°´T42%¡A¬°¦ó¦p¦¹üL¡H
¬ODupilumab ¤T´Á¹ï·Ó组¡A²Ä8¶g°´T 21%-23%¡Aªºªñ2¿¡H
ÁÙ¦nESAI-75/¬°0%¡A«á±ªºESAI-90/IGA0,1·íµM¥ç¬°¹s0% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤U¤È 11:11:00
²Ä 3844 ½g¦^À³
|
¥t¥~600mg ¥§¡¤U°¦Ü50% ªº®É¶¡³Ì§Ö¡A¤ñ²v°ª(3/3)¡A16¶g«áÄ~Äò¥Î¨ì ¤@¦~ªº¤ñ¨Ò±N¤ñdupiluma 61%¥ª¥k¼W¥[«D±`¦h . ¬OASLAN004 «¤j§Q¦h |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤U¤È 10:59:01
²Ä 3843 ½g¦^À³
|
¥xÁÞ¤j,
IGA 0.1 ¤ÎESAI-90 , ½T¹ê¶·n®É¶¡¡AÅý¥Ö½§¦^´_°·±d¡C
400mg/600mg ªºESAI ²Ä8¶g´N¹F67%,
Y¦pDupilumab IGA 0.1/ESAI-90 , ¥ÑESAI-75° 52%/48%¡X¡X(1) °¦ÜIGA 0/1 38%/31% ¡X¡X¡]2) ESAI -90 36%/30%¡X¡X¡]3)
(2)/(1)=38%/52%=73%°´T ¡X¡X31%/48%=64.5%
(3)/(1)=36%/52%=69% ¡X¡X30%/48%=62.5%
ASLAN004 16¶g (°²³]ESAI-75=67%) ESAI-90 ´Á±æÈ = 67%x62.5%~69%=41.8%~46.3% IGA 0/1 ´Á±æÈ = 67%x64.5%~67%=43.2%~44.9% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/2 ¤U¤È 10:32:33
²Ä 3842 ½g¦^À³
|
¤Ñ©R¤j ¤½¥q±Ú¸sÂX¼W18¤H¬O¥Î600mg , ¥[¤W쥻6¤H¬O¦h¾¯¶q 600mg ²Õ ¦Xp24¤H 600mg ²Õ IGA 0/1 ²Ä8¶g¼Æ¾Ú¬O 33% ²Ä16¼W¥[´T«×¦pªG°Ñ·Ó Lebrikizumab phase2b IGA 0/1 ¦b²Ä8¶g¬O31% ²Ä16¶g¼W¥[¨ì45% ¼W¥[14% % change in pruritis NRS Lebrikizumab phase2b ¦b²Ä8¶g¬O46 % ²Ä16¶g¼W¥[¨ì62% ¼W¥[16%
ASLAN004 IGA 0/1 ¦³¥i¯à¼W¥[¨ì 47% ©Î §ó°ª ( ¦³¶W¶VDupilumab IGA 0/1 36%-38% ªº¼ç¤O) ASLAN004 % change in pruritis NRS ¦b²Ä8¶g¸¨¦b 39 ¨ì48 % ²Ä16¶g¦³¼W¥[¨ì55%¨ì64% ªº¼ç¤O (¦³¶W¶VDupilumab 44%-51% ªº¼ç¤O) ´Á¤¤¼Æ¾Ú ASLAN004¦b¦w¥þ©Ê @¨ü©Ê EASI -50 EASI- 75 EASI -90 §¹³Ó Dupilumab , ¦pªG¦b¥[¤W IGA 0/1 »P % change in pruritis NRS ¤]¯à§¹³ÓDupilumab ¼ç¤O¹ê¦b¤£®e¤pòó
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤U¤È 08:46:34
²Ä 3841 ½g¦^À³
|
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
ASLAN004 p.8/9/10/11/13 vs dupilumab p.17
ASLAN004 400mg/600mgx¨C¶g¤@°w x8¶g vs Dupilumab ¨C¶g¤@°wx16¶g
(¤@).400mg/600mg QW(¨C¶g¤@°w/8¶g)
EASI-50 83%/100% EASI-75 67%/67% EASI-90 67%/33% IGA0/1 17%/33%(¥Dn«ü¼Ð)¡X¡X67%ªºESAI ,IGA 0.1 =17% , ¼Æ¾Úª½ªº©_©Ç¡AIGA0.1 ¤é«á¥²¤W¤Éªñ67%
(¤T)¹ï·Ó²ÕPlacebox8¶g
EASI-50 40% EASI-75 0% EASI-90 0% IGA0/1 0%(¥Dn«ü¼Ð)
¡X¡X¡X¡X¡X¡X Dupliumab 3´Á ¤¤-««×AD, 2ÓSOLO1/SOLO2 Á{§Éªº«ü¼Ð p,17
(¤@).300 mg QW(¨C¶g¤@°w/16¶g)¡A°_©l¶q600mg
EASI-50 61%/61% EASI-75 52%/48% EASI-90 36%/30% IGA0/1 38%/31%(¥Dn«ü¼Ð)
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 25%/22% EASI-75 15%/12% EASI-90 8%/7% IGA0/1 10%/8%(¥Dn«ü¼Ð) |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤U¤È 08:15:05
²Ä 3840 ½g¦^À³
|
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb
¤½¥q²¤¶¤¤
p7 vs. p17
°ò缐ªºPK ¤ñ¸û
ASLAN004 ¤Ï¦Ó§ó±µªñ Dupilumab ¤T´Á¤§°ò缐¼Æ¾Ú °ò½u¼Æ¾Ú𠃊ebrikizumab 2b ¤Ï¦Ó¤ñASLAN004 ¤Îdupilumab ¸û»´¯g
¬Ý§¹§ó¥[½T©wASLAN004 ¯uªº¤ñDupilumab ,¦P¼Ë¨C¶g¤@°wªº¼Ð·ÇÀøªkÀø®Ä±j«Ü¦h,«Ü¦h
(1)AS𠃊AN004 400mg-600mg-placebo//(2) dupilumab 300mg/qw s1-s2-placebo//(3)Lebrikizumab
EASI score ¡V mean¡C (1)30.9~32.5-p33.9 //(2) 33.2-31.9-(p 34.5-33.6)¡]3)25.5-p28.9 Patients with IGA 4 BSA ¡V mean ¡]1¡^17%-67%-p60%//¡]2)48%-47%-(p49%-49%)//(3)29%-p39% BSA ¡V mean (1)59.8%-56.3%-p59.8%//(2)56%-52%-p58%-54%//(3)40%-p47%
Abbreviations EASI: Eczema Area and Severity Index IGA: Investigator Global Assessment BSA: Body Surface Area
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¯T10148959 |
µoªí®É¶¡:2021/3/2 ¤U¤È 07:50:06
²Ä 3839 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤U¤È 06:38:15
²Ä 3838 ½g¦^À³
|
½Ķªº¦n±M·~! ÁÂÁ ¥xÁÞ¤j |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/2 ¤U¤È 06:28:42
²Ä 3837 ½g¦^À³
|
½Ķ¤£©ö ¦³¿ù½Ð§ó¥¿
°õ¦æºKn¡V¥¿±ªº´Á¤¤¼Æ¾Ú • §Ú̬۫H¥Ö½§¬ìÂå¥Í©M¯f±w¥¿¦b´M§ä¨ä¥L²§¦ì©Ê¥Ö½§ª¢ªvÀø¿ï¶µ---¦b§ïµ½Àø®Ä¡A¦w¥þ©Ê©Mµ¹ÃĤ覡¤W«Ü¦³¾÷·| • ASLAN004¬O¹v¦VIL-13R¥þ·sªº§ÜÅéÃĪ«¡A¥i³q¹L2«¬¨üÅéªýÂ_IL-4©MIL-13«H¸¹¶Ç»¼ • è¥XÄlªºÁ{§É¼Æ¾ÚÅã¥Ü¥X¨ã¦³¼ç¤OªºÄvª§ºA¶Õ¡A¯à»P²{¦³Àøªk°Ï¹j • ¦b»P¦w¼¢¾¯²Õ¤ñ¸û¤U¨Ì¾¯¶q¤£¦P¦b©Ò¦³Àø®Ä«ü¼Ð¤W§¡¯à¬Ý¥X±j¦Ó¦³¤O§ïµ½ªº¼Æ¾Ú¹Ïªí • ¦b©Ò¦³´ú¸Õ¾¯¶q¤U§¡@¨ü©Ê¨}¦n • ±Ú¸sÂX¼WÄ~Äò©Û¶Ò¡A¹wp¦b2021¦~¤¤±N¤½§i¥þ±§¹¾ãªº¬ã¨s¸ê®Æ¤ÀªR¡A¹wp2bÁ{§É¸ÕÅç±N¦b2021¦~¤U¥b¦~¶}©l 3 ´Á¤¤¼Æ¾ÚÅã¥Ü¥X±j¦Ó¦³¤O¥B¦³®t²§©Êªº¦w¥þ©Ê©M¦³®Ä©Ê¤§¼Æ¾Ú¹Ïªí
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤U¤È 05:44:52
²Ä 3836 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/2 ¤U¤È 05:21:38
²Ä 3835 ½g¦^À³
|
¤Ñ©R¤j ¥i¥H¥Î³oÓºô¶¸Õ¸Õ ½Ķ¤ñGOOGLE¦n¦h¤F www.deepl.com/home
执¦æºKn - 积Ì媺临时数Õu -• §Ú们¬Û«H¥Ö肤¬ì医¥Í©M±wªÌ¥¿¦b寻§ä§ó¦hªºADªv疗¤è®×--¦³Éó会§ïµ½疗®Ä¡B¦w¥þ©Ê©M剂¶q¤è®× -• ASLAN004¬O¤@Ïú·s«¬ªº¡B针对IL-13Rªº¤@类§ÜÊ^¡A³q过2«¬¨üÊ^ªý断IL-4©MIL-13ªº«H号传导¡C -• ·s¥X现ªº临§É数Õu显¥Ü¥X¨ã¦³竞争¤Oªº¯S点¡A¦³¥i¯à区别¤_现¦³ªº疗ªk -• 稳°·ªº剂¶q¨Ì赖©Ê疗®Ä¦±线显¥Ü¡AÉO¦w¼¢剂¬Û¤ñ¡A©Ò¦³疗®Ä终点§¡¦³§ïµ½¡C -• ¦b©Ò¦³测试剂¶q¤U³£¯à«Ü¦n¦a@¨ü -• 扩®i队¦C继续©Û¶Ò¡A预计2021¦~¤¤´Á§¹¦¨¥þ³¡¬ã¨s读数¡A2b´Á预计¦b2021¦~¤U¥b¦~ûD动¡C 3 ¤¤´Á数Õu显¥Ü¡A该药¨ã¦³üL¤jªº¡B®tÉݤƪº¦w¥þ©Ê©M¦³®Ä©Ê¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/2 ¤U¤È 05:11:27
²Ä 3834 ½g¦^À³
|
¤µ¤Ñ¤~¬O¤ÏÀ³ªÑ»ù³Ì¦å²O²Oªº¤@¤Ñ½T©w¾_Àú·|«D±`¤j ! ¬Q¤Ñ°l¦b6.Xªº§ë¸êªÌ¤µ¤Ñ¤£ª¾¹D·|«ç¼Ë°Ê§@ ! ¤j®an§¤Ã¤F !! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤U¤È 04:18:14
²Ä 3833 ½g¦^À³
|
¥xÁÞ¤j.
¥i§_¥Î±zÂå¾Ç±M·~À°¦£Â½Ä¶¥H¤U ,´Á¤¤¸Ñª¼µ²½×(Google ½Ķ ¯uªº¤£¦æ)
ir.aslanpharma.com/static-files/5af23249-0b59-4bb1-95eb-199556171feb p.3
Executive summary ¡Vpositive interim data • We believe dermatologists and patients looking for additional AD treatment options ¡Vopportunity to improve on efficacy, safety and dose regimen • ASLAN004 is a novel, first-in-class antibody targeting IL-13R, blocking both IL-4 and IL-13 signalling through the Type 2 receptor • Emerging clinical data demonstrate competitive profile with the potential to differentiate over existing therapies • Robust dose dependent efficacy profile showing improvement compared to placebo across all efficacy endpoints • Well-tolerated at all doses tested • Expansion cohort continues to recruit with full study readout expected in mid-2021, Phase 2b anticipated to initiate in 2H 2021 3 Interim data demonstrates a robust and differentiated safety and efficacy profile. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/2 ¤U¤È 04:08:29
²Ä 3832 ½g¦^À³
|
·sÃÄ20¦~±M§Q«OÅ@´Á¬Û·íªø¡AÁÙ¯à§â¬ãµo®É¶¡¦©°£¡A¥H©µªø±M§Q«OÅ@´Á¡A¬ãµo´Á¶¡¦p¦³·sµo²{¤S¥i¦A¥Ó½Ð±M§Q¡A¦A«·sºâ°_¡A¼h¼h«OÅ@¡AÅý±M§Q®É¶¡µo´§¨ì·¥¤j¤Æ ¥H¤U¸ê°T¥i参¦Ò¤@¤U www.stockfeel.com.tw/%E5%B0%88%E5%88%A9%E6%B3%95%E8%A6%8F/ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤U¤È 03:43:49
²Ä 3831 ½g¦^À³
|
18¤Hªº¸ê®Æ¡A¦p¬O·sM〇A¯uªº¤£¯à¥Nªí¤°»ò¡I ¦ý ASLAN004 1bÁ{§É ¬O¦bÅçÃÒ¤w³QDupilumab/Lebrikiumab/Talkiumabµ¥¤TÃÄÅçÃÒ¹Lªº TYPE II ½Æ¦X¨üÅé µoª¢¹L±Ó¸ô¸gM0A(§@¥Î¾÷Âà)
2021¦~5¤ë31¤ê ¥ª¥k¸Ñª¼ , ASLAN004©µ¦ù©ÊÁ{§É600mg ¤w¼W¥[¤H¼Æ ¨ì24¤H(ì¥ý18¤H¡C) ¥[²Ä¤T²Õì¥ý6¡Ï2 , ¦@32¤H
PÈ<0.05 ¡A¯u¥¿©M¹ï·Ó²Õ¦³²Îp¤Wªº©úÅã®t²§¡C¤è¯à¶ë¦í±y±y¤§¤f¡C
¡X¡X¡X¡X¡X ¥|Ãļйv§@¥Î¦ì¤l¤£¦P¡A Àø®Ä ¦ôp ASLAN004 >= Dupilumab>Lebrikiumab75%>Tralokinumab50% ¥´°w频²v§óÀuASLAN004 ¥|¶g¤@°w vs ¨ä¥L¤G¶g¤@°w
°Æ§@¥Î¡GASLAN004µLDupi1upmabªº结½¤ª¢ ¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K
Lebrikizumab & Tralokinumab , ¥u¯àªýÂ_IL13 °T¸¹¶Ç»¼¡AµLªk§¹¥þªýÂ_IL4 °T¸¹¶Ç»¼¡A¥\¯à¤j´î75%~50%¡C
µLªkªýÂ_ A¸ô®| (2): IL4 & IL-4R£\ ¦A±µ¦XIL-13R£\1 , ²Õ¦¨ªºII«¬¨üÅé, ¦]¦Ó±Ò°Ê²ÓM¤ºªº«H¸¹¶Ç»¼¡A¶i¦Ó¬¡¤ÆÂà¿ý¿E¬¡³J¥Õ6 (signal transducer and activator of transcription 6, STAT6) ¶Ç¾É¸ô®|,¾ÉP¹L±Ó©Êµoª¢¤ÏÀ³¡C
¥u¯àªýÂ_B¸ô®| : Lebrikizumab ±µ¦X IL13 ªºB¡BCÁ³±Û , ¦ýIL13 & IL-13R£\1 ¤´¥i±µ¦X¡A¥u¬OµLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II«¬ ¨üÅé Tralokinumab ±µ¦XIL13 ªºA¡BDÁ³±Û ¨Ï IL13 & IL-13R£\1 µLªk±µ¦X¡A¤]µLªk¦A±µ¦X IL-4 R£\,µLªk²Õ¦¨ II «¬¨üÅé
¥H¤W¸ÑÄÀ Tralokinumab ¤T´ÁÁ{§É¹w«á«ü¼Ð¡AÀø®Ä´X¥G¥u¦³Dupilumab 50%¡C
¦]Lebrikizumab , IL13 & IL-13R£\1 ¤´¥i±µ¦X¦û¾Ú IL-13R £\1, ¼vÅT0~50% IL4 °T¸¹¶Ç»¼¡C ¤]¸ÑÄÀ Lebrikizumab ¤G´ÁÁ{§É¹w«á¥Dn«ü¼Ð»P¹ï·Ó²Õ¤ñ È ¥u¦³Dupilumab 50%~75%¡C
ASLAN004 MOA -¼v¤ù aslanpharma.com/drug/aslan004/
2.Dupilumab MOA -¼v¤ù
www.dupixenthcp.com/atopicdermatitis/about/mechanism-of-action
MOA www.tsim.org.tw/journal/jour29-6/02.PDF?fbclid=IwAR2B85aLqBUAt5agx6K7u0NkCGTGpr7w6HDCagHhLuu54ZH7FEqHMAdXG3M |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤U¤È 03:27:20
²Ä 3830 ½g¦^À³
|
×¥¿ ¦X¤@ON101è¥Ó½Ð¬ü°ê±M§Q, ¸¹ºÙ18¦~«OÅ@´Á¡C¨ì2039¦~
www.evaluate.com/vantage/articles/news/snippets/early-data-boost-aslan-dont-ignore-red-flags ¥Lªººô¶¡A©ú©ú¦³¨È狮¶RÂ_CSLÅv§Qªº¦U´Á´Ú¤ä¥I±ø¥ó
²Ä¤@µ§´Ú¶µ3¤d¸U¬ü¤¸, ¦b¶}©l¤T´ÁÁ{§É®É¤ä¥I¡A«ç»ò·|¤U
The downsides: ¡¥004¡¦s inventor CSL is owed considerable milestone payments, /
downside ¡G¡¦004ªºµo©ú¤HCSL³Q¤í¤F¥iÆ[ªº¨½µ{¸O¥I´Ú¡A
¸C²´»¡ x¸Ü
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/3/2 ¤U¤È 03:16:27
²Ä 3829 ½g¦^À³
|
¤U°À£¤O½u¡A®M¨c½æÀ£¥XÅ¢¡A©M§Ú¤@¼Ëªº¤p¸ê±Ú¡A³Ì«á¤W¨®ªº¾÷·|¡A¦b¨Ó¥i¯à¤£¬O¤p¸ê±Ú¯àª±ªº¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤U¤È 03:12:28
²Ä 3828 ½g¦^À³
|
¨È·à±d2019¦~5¤ë31¤é¡A©MCSL ¦@¦P¶}µoªÌ¡A±ÂÅvµ¹¨È·à±dªº¥þ²y¶}µo¥Í²£µo®iÅv§Q¡C
¨È·à¶RÂ_»ù =¨½µ{ª÷ 0.35»õ¡A¨¥¦W¶}©l°µ¤T´Á®É¤ä¥I¡Ï ¨½µ{ª÷0.9»õ¬üª÷ ¡]¥i¯à¨úÃĵý®É¤ä¥I¡^ +³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷)=7.8»õ¬üª÷)+
(¥[¾P°â¤À¼í5%~<= 10%.)
³o½g¤å³¹¬O´c·N§ðÀ»¡A¤j¤jÌ¡A¥i専¶Kµ¹ ¨È·à±dªºªk°È
¬ü°ê³Ð·s¥Íª«»s¾¯ÃĤ@®Ö凖¤W¥««á¦³12¦~ªº«OÅ@´Á¡A¤£±o¦³¥é¥ÍÃĤW¥«.
CSL¬O¥«È1¥ü¥x¹ôªº¤½¥q¡A¤°»ò±M§Q¨ì´Á¡H¶}ª±¯º¡I
Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor £\1 N.T. Redpath, Y. Xu, N.J. Wilson, L.J. Fabri, M. Baca, A.E. Andrews, H. Braley, P. Lu, C. Ireland, R.E. Ernst, A. Woods, G. Forrest, Z. An, D.M. Zaller, W.R. Strohl, C.S. Luo, P.E. Czabotar, T.P.J Garrett, D.J. Hilton, A.D. Nash, J.G. Zhang, N.A. Nicola Biochem. J. (2013), Note: antibody 10G5-6 is ASLAN004
2013¦~¤~¥Ó½Ðªº±M§Q¡A«ç·|§Ö¹L´Á¡H
¦X¤@ON101è¥Ó½Ð¬ü°ê±M§Q, ¸¹ºÙ22¦~«OÅ@´Á¡C
¤H¬õ¬O«D¦h¡C
REGN ªºDupilumab ±N³QASLN004 «Â¯Ù¡A¨ä¥LªºAD¥Íª«»s¾¯¤£¬O¥L̤GÃĪº¹ï¤â¡C
¤j®a¦b¥Ö¥Ö®À¡C
¥un¦³»ùÈ¡AÁ`¦³ªÑ»ù¤ÏÀ³É]Ȫº¤@¤Ñ.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¬õ¹Ð¦³¹Ú10150039 |
µoªí®É¶¡:2021/3/2 ¤U¤È 03:05:25
²Ä 3827 ½g¦^À³
|
¬Q±ß¹Ú¨£©Ô¤F¤@°ïÂû³J¿|¡A¯u´c¤ß¡A°_§É¤~ª¾¹D ¸Ñª¼¤F ª©¤W¦³¦U¦ì±M·~ªº¤j¤j°µ»âÀY¦Ï¡A¤Ñ¤Ñ©êªÑºÎ¤jı |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/2 ¤U¤È 02:50:54
²Ä 3826 ½g¦^À³
|
©I¥s¤Ñ©R¤j ½Ð°Ý§A¹ï³o°OªÌ¤å³¹ªº¬Ýªk ! www.evaluate.com/vantage/articles/news/snippets/early-data-boost-aslan-dont-ignore-red-flags ¥L¬O»¡¦³³\¦h±M§Q·|¦b2027/10¤ë¨ì´Á ....
§Ú¬d¤F¤@¤U¬ÛÃöªº¸ê®ÆÁöµM¨ì´Á¦ý¬OÁÙ¬O¥i¥HÄò¬ù¦ý¬On¥I¶O !
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GPica10150664 |
µoªí®É¶¡:2021/3/2 ¤U¤È 12:08:11
²Ä 3825 ½g¦^À³
|
2-3¦~«á¡A¤]³\·|¦³¤H»¡: ´¿¸g¦³¤@¤ä¦³¼ç¤OªºªÑ²¼©ñ¦b§Ú±«e¡A§Ú¨S¦³¬Ã±¤¡Aµ¥§Ú¥¢¥hªº®ÉÔ§Ú¤~«á®¬²ö¤Î¡A¤H¥@¶¡³ÌµhWªº¨Æ²ö¹L©ó¦¹¡C¦pªG¤W¤Ñ¯à°÷µ¹§Ú¤@Ó¦A¨Ó¤@¦¸ªº¾÷·|¡A§Ú·|¹ï¨º°¦ªÑ²¼°µ¤@¥ó¨Æ¡G¥u¶R¤£½æ¡C¦pªG«Dn¦b³o¤äªÑ²¼¤W¥[¤W¤@Ó´Á¡A§Ú§Æ±æ¬O¡K¡K¤@¸U¦~¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/2 ¤W¤È 11:40:47
²Ä 3824 ½g¦^À³
|
¦bµ¹¤j®a¤p§Ìªº¤@ÂI©å¨£ ¬Q¤Ñ¼Æ¾Ú©Ô°ªªÑ»ù¤S¦^¶^,³o¬O¥¿±`ªº²{¶H,µ´¤j³¡¤À§ë¾÷«È¤§«e®Ú¥»¤£ª¾¹DASLAN004¬Æ¦Ü¤£ª¾¹DASLN³o®a¤½¥q,³o¨Ç§ë¾÷«È¤£ºÞ¼Æ¾Ú¤º®e´N²r°l°ªµM«á½L¤¤¤U¶^´N°±·l¬å±¼,¦ýÀHµÛ¤µ¤Ñ¼Æ¾Ú¤½¶}©ú®Ô¤Æ,¤@©w·|¦³±M·~ªº§ë¸ê¾÷ºc¶}©l¤ÀªR¼Æ¾Ú¨Ãµû¦ô§ë¸ê¤ñ«»P¤¶¤J»ù¦ì,²{¦b¶^¤Ï¦Ó¬O°·±dªº¦]¬°Äw½X¥¿¦b³Q³o¨Ç¾÷ºcÀqÀq¾ß¨«,µ¥¨ìÄw½X°®²b«á§An¶R³£¨Ó¤£¤Î¤F ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤W¤È 11:35:09
²Ä 3823 ½g¦^À³
|
²Ä¤@Ó½Õ°ªASLN ¥Ø¼Ð»ù¨ì10¬ü¤¸ªº¤ÀªR³ø§i(¤§«e¥Ø¼Ð»ù6¬ü¤¸)
Piper Sandler±NAslan Pharmaªº»ù®æ¥Ø¼Ð´£°ª¦ÜµóÀY³Ì°ª
2021¦~3¤ë1¤é¡A¤W¤È11:01 ETASLAN Pharmaceuticals Limited¡]ASLN¡^¡A§@ªÌ¡GDulan Lokuwithana¡ASA·s»D½s¿è Piper Sandler¦b¯SÀ³©Ê¥Öª¢ªº1´Á¬ã¨s¤¤«Å¥¬¨ä³æ§J¶©§ÜÅéASLAN004ªº¤¤´Á¤¤´Áµ²ªG¬°¶§©Ê«á¡A±NASLAN»sÃÄ¡]ASLN + 22.3¢H¡^ªº»ù®æ¥Ø¼Ð±q¨CªÑ6.00¬ü¤¸¤W½Õ¦ÜµØº¸µó°ªÂI¡A¦Ü10.00¬ü¤¸¡C µM¦Ó¡A¤ÀªR®v·R¼wµØ¡PA¡P©Z¯Á¤Ò¡]Edward A. Tenthoff¡^¤Î¨ä¹Î¶¤±Nµû¯Åºû«ù¦b¼W«ù¤£ÅÜ¡A¦Ó·sªº»ù®æ¥Ø¼Ð·N¨ýµÛ¸û¤W¤@¥æ©ö¤é¤Wº¦¬ù125.7¢H¡C ÀHµÛ²Ä¥|Ó¡]ÂX®i¡^¶¤¦C¡]600²@§J¡^ªº¤J¾Ç¥Ó½Ð¡A¸Ó¤½¥qª`·N¨ì¦³¥i¯à¦b2021¦~¤¤´Á«Å¥¬¸Ó¬ã¨sªº§¹¾ã¡A«Dª¼¼Æ¾Ú¡C ¤ÀªR®v¹w´ú¡A¦b400²@§J©M600²@§J¥Ö¤Uª`®g¯SÀ³©Ê¥Öª¢®É¡AASLAN004±N¦b2H 2021¦~2b´Á¶}©l¬ã¨s¡A¤ÀªR®vÁÙ¹wpAslan³Ì²×±N¦b¨ä¥L¹L±Ó©Ê¯e¯f¤¤µû¦ôASLAN004¡C 1¤ë¥÷¡A¸Ó¤½¥q«Å¥¬¡A¼Æ¾ÚºÊ±±©eû·|¬°¸Ó¸ÕÅ窺³Ì«áÂX®i¶¤¦C¤¤±wªÌ¤J²Õªº¶}©l¶}¤Fºñ¿O¡C
Aslan Pharma price target raised to a Street-high at Piper Sandler
Mar. 01, 2021 11:01 AM ETASLAN Pharmaceuticals Limited (ASLN)By: Dulan Lokuwithana, SA News Editor Piper Sandler has upped the price target of ASLAN Pharmaceuticals (ASLN +22.3%) to a Wall Street-high of $10.00 from $6.00 per share after the company announced positive interim results for its monoclonal antibody ASLAN004 in a Phase 1 study in atopic dermatitis. The analyst Edward A. Tenthoff and the team have however kept the rating unchanged at overweight, and the new price target implies ~125.7% upside to the previous close. With enrollment for the fourth (expansion) cohort (600mg) ongoing, the firm notes a possible announcement of full, unblinded data from the study in mid-2021. Predicting the initiation of a Phase 2b study in 2H 2021 for ASLAN004 in atopic dermatitis with 400mg and 600mg subcutaneous injections, the analysts also expect Aslan to ultimately evaluate ASLAN004 in other allergic conditions. In January, the company announced that the Data Monitoring Committee greenlighted the start of patient enrollment for the final expansion cohort of the trial. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤W¤È 10:45:52
²Ä 3822 ½g¦^À³
|
ir.aslanpharma.com/static-files/0497e948-4fc0-44fc-bddd-0fdd7b88cd4b
³Ì·sªº¤½¥q²¤¶
¦³¥»¦¸¸Ñª¼ªº¸Ô²Ó³ø§i
¤º®e¼W¥[«Ü¦h
Mar 01,2021úêCompany Presentation March 2021
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/2 ¤W¤È 10:37:50
²Ä 3821 ½g¦^À³
|
ASLAN004 ¤@´Á¹êÅç³]p Investigator¡¦s Global Assessment (IGA) Score of 0 or 1 at Week 8 »P°ò·Ç½u¤ñ¸û¦³¤U°¤j©óµ¥©ó¤G¤À¨S¦³¦³ºâ¶i¥h¡A ¦pªG¦³ºâ¶i¥h°t¦XÆ[¹î®É¶¡¨ì²Ä¤Q¤»¶g¡A§ïµ½¤ñ²vÀ³¸Ó·|§ó°ª
Dupilumab ¤T´Á¤£¦P Investigator¡¦s Global Assessment (IGA) Score of 0 or 1 and Reduction From Baseline of ≥2 Points at Week 16 »P°ò·Ç½u¤ñ¸û¦³¤U°¤j©óµ¥©ó¤G¤À¤]¦³ºâ¶i¥h
Primary Outcome Measures : Percentage of Participants With Investigator¡¦s Global Assessment (IGA) Score of 0 or 1 and Reduction From Baseline of ≥2 Points at Week 16 [ Time Frame: Week 16 ] IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of 0 or 1 and a reduction from baseline of ≥2 points at Week 16 were reported. Values after first rescue treatment were set to missing and participants with missing IGA scores at Week 16 were considered as non-responders. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/2 ¤W¤È 09:58:34
²Ä 3820 ½g¦^À³
|
ÃĪ«ª¾Ãѱ¤p§Ì¤£¦p¦U¦ìª©¤W«e½ú¥R¨¬,¦ý¬OªÑ²¼«ù¦³¤ßºA§Æ±æ¥i¥Hµ¹¤j®a¤@ÂI«Øij! ¤j®anª¾¹D¬Q¤éªº¶}°ª¨«§C,¬O¥«³õ§Q¦h¤ÏÀ³«á°±§Q½æÀ£,¤d¸U¤£n¦³¥¢±æªº¤ßºA,¦]¬°¤µ¦~¤w¸gº¦186%¤F ¥Ø«e¼Æ¾Ú¬O¥¿¦V¸ÑŪ,ªÑ»ùÀ³¸ÓÁÙ¬O·|¨B¤JÀ³¸Ó¦³»ùÈ,¦ý³oº©ªøªº´Á¶¡ªÑ»ù°ª§C°_¥ñ¥i¯à·|¶^¯}¤j®a²´Ãè...¦³¥i¯à¨«§C¨ì3¬ü¤¸¥H¤U¤]¦³¥i¯à¬ð¯}8¬ü¤¸¤§¤W,¦pªG§A³]©w°±§Qor°±·l¥Ø¼Ð»ù¤£¦b¦¹°Ï¶¡3~8,«Øij¤£n¤Ñ¤ÑÆ[½LÁקK±¡ºü°_¥ñ¤Ó¤j½L¤¤¤âÄo½æ½æ¥X... ¬Q¤Ñ¤§«e¼Æ¾Ú©|¥¼¤½¶}«eÁÙ¬O¤ßÅåÁx¸õ,²{¦b¤w¸g¤½¶}¥¿¦V¼Æ¾Ú¤F,À³¸Ón°í©w¦Û¤vªº«H¤ß! ¤S¥[¤W¤Ñ©R¤j¥x¿}¤j«e½úªºµL¨pªº©^Äm»P«Øij,Åý§Ú̦b¯í¯í¤j®ü¦³¤F¤è¦V,¦pªG¤£¬O¤Ñ©R¤j°í«pªº¹ê¤O¤£©w®ÉªºPO¤åµ¹§ÚÌ«H¤ß,§Ú̳o¨Ç¥xÆW¦À³¸Ó¦¦b¥xÆW¤U¥«ÂàADR¤W¥«¨S´X¤Ñ´N½æ¥ú¥ú¤F,¨Ò¦pT¤j1.7¥ª¥k½æ¥X(¤£¹LT¤j¥i¤w´N¬O³]©wµu½uÀò§Q¤Fµ²!¦½æ¦¨É¨ü,¬Ý¥L¤§«eªºPO¤å,¥LÀ³¸Ó¬O¥x¹ô5¶ô¿úªº¦¨¥»!´XÓ¤ëµu½uÁȤ@¿(¦Ê¸U)¤]¬O«Ü´Îªº§Q¼í),¦ý¦pªG§A¬Oì©l¦ÑªÑªF,¥Ø«eè¦n¬O·l¯q¨â¥®É§ó¥²¶·n°í©w«H¤ß,¤d¸U¤£nı±o¦Û¤v¤pÁȩάO¨SÁ«·l«O¥»«á´N½æ¥X...¥i¯à¹LÓ¤@¦~§A·|µo²{¦Û¤v¤S»P°]´I¦Û¥Ñ®t¨¦Ó¹L ! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/2 ¤W¤È 09:23:49
²Ä 3819 ½g¦^À³
|
Àã¯l±¿n©MÄY«µ{«×«ü¼ÆESAI EASI¬O¦bÁ{§É¸ÕÅ礤¥Î¨Óµû¦ô²§¦ì©Ê¥Ö½§ª¢¡]AD¡^ªºÄY«µ{«×©Mµ{«×ªº¶qªí,¦bEASI¤¤¡Aµû¦ô¤FADªº¥|ºØ¯e¯f¯S¼x¡]¬õ´³¡A®û¼í/¦¨¤Õ¡A鸨©MaÄö¼ËÅÜ¡^ÄY«µ{«×¬°0¡]¤£¦s¦b¡^¦Ü3¡]ÄY«¡^¡C¨CÓ¨Å鳡¦ì¡]ÀY³¡¡A¤âÁu¡AÂß°®©M»L³¡¡^ªº±o¤À¬Û¥[¡C¤À°tµ¹¤HÅé¦U³¡¤Àªº¨Åéªí±¿n¡]BSA¡^¦Ê¤À¤ñ¤À§O¬O¡GÀY³¡10¢H¡A¤âÁu20¢H¡AÂß·F30¢H©M»L³¡40¢H¡C¨CÓ¤pp¤À¼Æ¼¥H¸Ó°Ï°ì¥NªíªºBSA¡C¦¹¥~¡A®Ú¾Ú¸Ó°Ï°ì¨üAD¼vÅTªº¥Ö½§ªº¦Ê¤À¤ñ¡A¬°¨CÓ¨Å鳡¦ì¤À°t°Ï°ì±o¤À0¨ì6¡G0¡]µL¡^¡A1¡]1¢H¨ì9¢H¡^¡A2¡]10¢H¨ì29¡^ ¢H¡^¡A3¡]30¢H¦Ü49¢H¡^¡A4¡]50¢H¦Ü69¢H¡^¡A5¡]70¢H¦Ü89¢H¡^©Î6¡]90¢H¦Ü100¢H¡^¡C¨CÓ¨Å鳡¦ì¤À¼Æ³£¼¥H¨ü¼vÅTªº±¿n¡C©Ò±oªºEASIµû¤À½d³ò¬°0¨ì72¤À¡A³Ì°ªªºµû¤À¿ö©úADªºÄY«µ{«×¸û®t¡C¤w«Øij°ò©óEASIµû¤ÀªºADÄY«µ{«×À³ÂkÃþ¬°¡G0 =²M´·¡F 0.1¦Ü1.0 =´X¥G²M´·¡F 1.1¦Ü7.0 =»´«×¡F 7.1¦Ü21.0 =¤¤«×¡F 21.1¦Ü50.0 =ÄY«¡F 50.1¦Ü72.0 =«D±`ÄY«¡CEASI-75ªí©ú»P°ò½u¬Û¤ñ§ïµ½¤F≥75¢H¡C
¦b´X¶µ¬ã¨s¤¤Àˬd¤FEASIªº¦³®Ä©Ê©M¥i¾a©Ê¡C20¡V22,22¦ôp¤FEASI©MSCORAD¤§¶¡ªº¬ÛÃö«Y¼Æ¥Hµû¦ô¦³®Ä©Ê¡CEASI©MSCORAD¤§¶¡ªº¬ÛÃö«Y¼Æ¬°¤¤«×¨ì°ª«× ¡]r = 0.84¦Ü³ø§i¤F0.93¡^ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/2 ¤W¤È 09:08:08
²Ä 3818 ½g¦^À³
|
¤°»ò¬OIGA IGA¬O¤@ºØ¤ÂI¶qªí¡A¥i¹ïADªºÄY«µ{«×¶i¦æ¥þ±ªºÁ{§Éµû¦ô¡A½d³ò±q0¨ì4¡A¨ä¤¤0ªí¥Ü²M´·¡A2ªí¥Ü»´«×¡A3ªí¥Ü¤¤«×¡A4ªí¥ÜÄY«AD¡C4±o¤À°§C»P§ïµ½¯gª¬©MÅé¼x¡C¦ý¬O¡A¦³¸ñ¶Hªí©ú¡AIGA¬O¬°Á{§É¸ÕÅç¦Ó³]pªº¡A¨Ã¥B³q±`¥Î©óÁ{§É¸ÕÅç¡A«Ü¤Ö¦bÁ{§É¹ê½î¤¤¨Ï¥Î¡C±µ¨ü¥»¦¸¼f¬dªºÁ{§É±M®a¸ÑÄÀ»¡¡A¦b¹ê½î¤¤¡AÂå®v·|§ó¥DÆ[¦aµû¦ô±wªÌªºAD¡]µû¦ôª¢¯g¯fÅܩάõ´³ (ESAI¡^¡A¦ÓµL»Ý¨Ï¥ÎIGA¡C¾Ú³ø¾É¡AIGAªºÃþ¤º¬ÛÃö«Y¼Æ¡]¬ã¨sªÌªºµû»ùªÌ¤º«H«×¡^¡]0.54¡^§C©ó³q±`»{¬°¥i±µ¨üªº¤ô¥¡]0.70¡^
www.ncbi.nlm.nih.gov/books/NBK539234/ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤W¤È 08:48:31
²Ä 3817 ½g¦^À³
|
6900¸U¬ü¤¸ªºªÑ¼Æ¥i¯à¨Ó¦p¤U :
¦¹¥~¡AºI¦Ü¥»©ÛªÑ»¡©ú®Ñ¼W¸É¤§¤é¡A¤w¦V¥_¬üªº¼¯®Ú¤j³q»È¦æµo¦æ¤F53,393,470ªÑ´¶³qªÑ¡]¥Nªí10,678,694ªÑ¬ü°ê¦s°U¾ÌÃÒ¡^¡A§@¬°¦s°U¤H¡A³o¨Ç´¶³qªÑ±N®Ú¾Ú¥»¨óijªº¥¼¨Ó¾P°â©Mµo¦æ¬ü°ê¦s°U¾ÌÃÒ¡]¦p¦³¡^«ù¦³¡C
In addition, as of the date of this prospectus supplement, 53,393,470 ordinary shares (representing 10,678,694 ADSs) have been issued to JPMorgan Chase Bank, N.A., as depositary, which are being held for future sales and issuances of ADSs, if any, under the Sale Agreement.
ªÑ»ù--
6900¸U¬ü¤¸/10,678,694ªÑadr=6.4¬ü¤¸
µu´Á¥i¯à¤Uרì¦p¤W6.4¬ü¤¸/ADR
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤W¤È 08:32:49
²Ä 3816 ½g¦^À³
|
www.sec.gov/Archives/edgar/data/1722926/000119312521063788/d145164d424b5.htm#supp_rom145164_1 2021¦~3¤ë1¤éªº¶Ò¸êp¹º,¦p¤W
¦¹¥~¡A¦p¤W©Òz¡A¥»¦¸µo¦æ«á¥ß§Yµo¦æ¦b¥~ªº´¶³qªÑ¼Æ¶q¤£¥]¬A ¡]i¡^§Ú̮ھÚÃÒ¨éµo¦æªº2025¦~2¤ë25¤é«D¤½¶}µo¦æªº25,568,180ªÑ´¶³qªÑ¡A¶Ò¶°¸êª÷Á`ÃB¬ù¬°1,800¸U¬ü¤¸§ÚÌ»P¨p¶Ò¤¤ªºÁʶRªÌñqªºÁʶR¨óij©Î¡mÃÒ¨éÁʶR¨óij¡n©Î ¡]ii¡^§Ú̦b¥»©ÛªÑ»¡©ú®Ñ¼W¸É¤é¤§«e°â¥Xªº8,862,972ªÑADS¡]¥Nªí44,314,860ªÑ´¶³qªÑ¡^¡A¦©°£¦þª÷«áªº²b¦¬¯q¬ù¬°2,150¸U¬ü¤¸¡A¦ý¦b¦©°£§ÚÌ©ó2020¦~10¤ë9¤é»PJefferies LLC©ÎJefferiesñqªº¡m¤½¶}¥«³õ¾P°â¨óijSM¡n©Î¡m¾P°â¨óij¡n¤Uªº¥ô¦óµo¦æ¶O¥Î¤§«e¡A¨ä¤¤12¤ë31¤é«á¥X°â¤F4,908,987ªÑADS¡]¥Nªí24,544,935ªÑ´¶³qªÑ¡^ ¡A 2020¦~¡A¦b¦©°£¦þª÷¦ý¥¼¦©°£µo¦æ¶O¥Î«eªº²b¦¬¯q¬ù¬°1,410¸U¬ü¤¸®Ú¾Ú»PJefferies¹F¦¨ªº¾P°â¨óij¡C
¦¹¥~¡AºI¦Ü¥»©ÛªÑ»¡©ú®Ñ¼W¸É¤§¤é¡A¤w¦V¥_¬üªº¼¯®Ú¤j³q»È¦æµo¦æ¤F53,393,470ªÑ´¶³qªÑ¡]¥Nªí10,678,694ªÑ¬ü°ê¦s°U¾ÌÃÒ¡^¡A§@¬°¦s°U¤H¡A³o¨Ç´¶³qªÑ±N®Ú¾Ú¥»¨óijªº¥¼¨Ó¾P°â©Mµo¦æ¬ü°ê¦s°U¾ÌÃÒ¡]¦p¦³¡^«ù¦³¡C¾P°â¨óij¡C
1800¸U¬ü¤¸¨p¶Ò+1410¸U¬ü¤¸(2021¦~«á¥X°â)/4,908,987ªÑADR=3210¸U¬ü¤¸
+¥¼¨Ó¤½¶}¶Ò¸ê6000¸U¬ü¤¸+900¸U¬ü¤¸. =1.01»õ¬ü¤¸.
2020¦~©³¸êª÷1430¸U¬ü¤¸ ------------------------ ¥¼¨Ó¥i¶ÒªÑ¼Æ ²z½×¤W7100¤dªÑ-4908¤dªÑ(2021¦~¤w¶Ò)=2192¤dªÑ
6900/2192=31¬ü¤¸/¨CªÑ----¥i¯à§_???
©Î³\¦³§ó¦hªÑ¼Æ¥i¶Ò.
---¤½¥qp¹º¤U¥b¦~ (1)2b --«-¤¤«×AD (2)¶}©lASLAN004¨ä¥L¾AÀ³µý(À³¬Oý³Ý) (3)ASLAN003 ¦ÛÅé§K¬Ì(Ms)
ASLAN004. ASLAN004 is a fully human monoclonal antibody that binds to the IL-13 receptor £\1 subunit (IL-13R£\1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. We have initiated a Phase 1 clinical trial investigating ASLAN004 as a therapeutic antibody for atopic dermatitis. A single ascending dose, or SAD, clinical trial in healthy volunteers was completed in the second quarter of 2019. In October 2019, we initiated a multiple ascending dose, or MAD, clinical trial in moderate-to-severe atopic dermatitis patients Interim results demonstrate a competitive profile with the potential to differentiate over existing therapies. We expect to report topline data from this trial in mid-2021. In addition, we plan to explore additional indications for ASLAN004 in the second half of 2021.
ASLAN003. ASLAN003 is an orally active, potent small-molecule inhibitor of DHODH. In preclinical studies, ASLAN003 was shown to be efficacious in various animal models of autoimmune disease. Recently published data demonstrated that out of six DHODH inhibitors tested, ASLAN003 had the lowest potential for hepatotoxicity despite being one of the most potent inhibitors of DHODH, suggesting that ASLAN003 has the potential to be best-in-class for the treatment of autoimmune disease. We are planning to develop ASLAN003 for the treatment of autoimmune conditions.
Additional Discovery Programs. We have established a joint venture called JAGUAHR Therapeutics Pte. Ltd. with Bukwang Pharmaceutical Co., Ltd., or Bukwang, a leading research and development focused Korean pharmaceutical company, to develop antagonists of the aryl hydrocarbon receptor, or AhR, an immune checkpoint inhibitor.
Recent Clinical Developments
ASLAN004 ¡V Multiple Ascending Dose Clinical Trial in Moderate-to-Severe Atopic Dermatitis
The randomized, double-blind, placebo-controlled MAD clinical trial evaluated three doses (200mg, 400mg and 600mg) of ASLAN004 delivered weekly via subcutaneous injection. Based on a review of blinded safety data, the highest dose, 600mg, was selected for the expansion cohort, which will recruit at least 24 additional patients. The primary endpoint is safety and tolerability. Secondary endpoints include efficacy at eight weeks as measured by improvement in the Eczema Area and Severity Index, or EASI, score, EASI-50, EASI-75, EASI-90, Investigators Global Assessment, or IGA,, pruritis numeric rating scale, or NRS, and Patient-Oriented Eczema Measure. The trial will recruit up to 50 moderate-to-severe atopic dermatitis patients and recruitment into the expansion cohort started in January 2021. We expect to report topline data from this trial in mid-2021. The trial was designed with 80% power to detect a 39% improvement in EASI compared to placebo at eight weeks. After completion of the MAD trial, we plan to initiate a Phase 2b dose-range finding trial in atopic dermatitis patients.
On March 1, 2021, we reported positive interim unblinded data from the first three dose cohorts (200mg, 400mg and 600mg) of the ongoing MAD clinical trial. The first three cohorts randomized 25 patients from the United States, Australia and Singapore. Three patients discontinued the trial due to restrictions imposed in response to COVID-19. Of the remaining 22 patients, 18 completed at least 29 days of dosing and assessment and were evaluable for efficacy. The average baseline EASI score of patients was 32.5 and the average IGA score was 3.4 (n=18). At week 8, the average reduction in EASI from baseline at therapeutic doses (400mg and 600mg cohorts) was 74% (n=9) compared to 42% (n=5) for patients on placebo. 89% of patients achieved EASI-50 versus 40% on placebo; 67% achieved EASI-75 versus 0% on placebo; 56% achieved EASI-90 versus 0% on placebo; and 22% of patients achieved IGA of 0 or 1 versus 0% on placebo. Peak pruritus improved after just one dose and continued to improve by an average of 46% relative to baseline at week 8 compared to 16% for patients on placebo. The proportion of patients with adverse events and treatment-related adverse events were similar across treatment and placebo arms. There were no treatment-related adverse events in the active arm that led to discontinuation.
Financial Update
While we have not finalized our full financial results for the fiscal year ended December 31, 2020, we expect to report that we had approximately $14.3 million of cash and cash equivalents as of December 31, 2020. This amount is preliminary, has not been audited and is subject to change upon completion of the audit of our consolidated financial statements as of and for the year ended December 31, 2020. Additional information and disclosures would be required for a more complete understanding of our financial position and results of operations as of December 31, 2020.
In addition, the number of ordinary share to be outstanding immediately after this offering as shown above does not include (i) 25,568,180 ordinary shares that we sold in a private placement on February 25, 2021 for gross proceeds of approximately $18.0 million pursuant to a securities purchase agreement we entered into with the purchasers in the private placement, or the Securities Purchase Agreement or (ii) 8,862,972 ADSs (representing 44,314,860 ordinary shares) that we sold prior to the date of this prospectus supplement for net proceeds of approximately $21.5 million after deducting commissions but before deducting any offering expenses under the Open Market Sale AgreementSM, or Sale Agreement, that we entered into with Jefferies LLC, or Jefferies, on October 9, 2020, of which 4,908,987 ADSs (representing 24,544,935 ordinary shares) were sold after December 31, 2020 for net proceeds of approximately $14.1 million after deducting commissions but before deducting any offering expenses under the Sale Agreement with Jefferies. In addition, as of the date of this prospectus supplement, 53,393,470 ordinary shares (representing 10,678,694 ADSs) have been issued to JPMorgan Chase Bank, N.A., as depositary, which are being held for future sales and issuances of ADSs, if any, under the Sale Agreement.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/2 ¤W¤È 08:30:07
²Ä 3815 ½g¦^À³
|
·PÁ¤ѩR¤jªº¸ê°T §Ú¤ñ¸û¦n©_ªº¬O ¦pªGn§ë¸ê¨È·à±dªº¤j¤á ¬°¤°»òn¦¬°Ñ¥[21¤¸©Î9.7¤¸ªº¨p¶Ò ¤£ª½±µ¦b¥«³õ¶R5.2¤¸ªº(ÁÙ¤£¥ÎÂê¦~) ¤Ñ©R¤j¥i¥HÀ°¤p§Ì¸Ñ´b¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸Ø±i10133098 |
µoªí®É¶¡:2021/3/2 ¤W¤È 08:07:19
²Ä 3814 ½g¦^À³
|
½Ð°Ý¤Ñ©R¤j
¶Ò¸ê1.5»õ¬ü¤¸·|¨ü¼vÅT¶Ü?? ±z¹w¦ôªº21¬ü¤¸/ADR·|½Õ¾ã¶Ü??
ÁÙ¬O1.5»õ¬ü¤¸ªº¶Ò¸ê´N¨S¦³¤F. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GAlvin10150583 |
µoªí®É¶¡:2021/3/2 ¤W¤È 08:03:43
²Ä 3813 ½g¦^À³
|
¤Ñ©R¤j ½Ð°Ý¤½¶}©Ó¾P6900¸U¬ü¤¸ADS©M¤§«e±z´£¨ìªº¶Ò¸ê1.5»õ¬ü¤¸¬O¦P¤@¥ó¨Æ¶Ü? ÁÂÁÂ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤W¤È 07:46:41
²Ä 3812 ½g¦^À³
|
¶Ò¸ê6900¸U¬ü¤¸ ¥i¶Ò7100¤dªÑadr
6900¸U¬ü¤¸/7100¤dªÑ=9.71 ¬ü¤¸-------¦¨¥\¶Ò¸ê³Ì§C¥§¡»ù |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤W¤È 07:31:37
²Ä 3811 ½g¦^À³
|
ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares March 01, 2021 16:01 ET | Source: ASLAN PHARMACEUTICALS LIMITED SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has commenced an underwritten public offering of $60.0 million of its American Depositary Shares (¡§ADSs¡¨) representing ordinary shares. In addition, ASLAN expects to grant the underwriters a 30-day option to purchase up to an additional $9.0 million of ADSs in the public offering on the same terms and conditions. All ADSs to be sold in the offering will be offered by ASLAN. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
ASLAN expects to use the net proceeds from the offering, together with its existing cash and cash equivalents, primarily to fund its planned ASLAN004 Phase 2b dose-range finding trial in moderate-to-severe atopic dermatitis patients. ASLAN is also required to repay $2.25 million of principal amount plus accrued and unpaid interest under its loan facilities entered into in October and November 2019 with the net proceeds from this offering. The remainder of the net proceeds, if any, will be used to fund new and other ongoing research and development activities, working capital and other general corporate purposes.
Jefferies LLC and Piper Sandler & Co. are acting as joint book-running managers for the offering.
The securities described above are being offered by ASLAN pursuant to a shelf registration statement on Form F-3, including a base prospectus, that was previously filed by ASLAN with the Securities and Exchange Commission (the ¡§SEC¡¨) and that was declared effective on February 11, 2021. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC¡¦s website located at www.sec.gov. Before you invest, you should read the preliminary prospectus supplement and accompanying prospectus and other documents we have filed with the SEC for more complete information about us and this offering.
ASLAN Pharmaceuticals«Å¥¬ÀÀ¤½¶}µo¦æ¬ü°ê¦s°UªÑ²¼ ¬ü°êªF³¡®É¶¡2021¦~3¤ë1¤é16:01 |¸ê®Æ¨Ó·½¡GASLAN PHARMACEUTICALS LIMITED 2021¦~3¤ë1¤é¡A·s¥[©Y·s¥[©Y-¥þ²y»â¥ýªº¥HÁ{§É¶¥¬q§K¬Ì¾Ç¬°°ò¦ªº¥Íª«»sÃĤ½¥qASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¥¿¦b¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A¤µ¤Ñ«Å¥¬¨ä¤w¶}©l¶i¦æ6000¸U¬ü¤¸ªº©Ó¾P¤½¶}µo¦æ¦Ê¸UªÑ¬ü°ê¦s°UªÑ²¼¡]¡§ ADS¡¨¡^¥Nªí´¶³qªÑ¡C¦¹¥~¡AASLAN§Æ±æ±Â¤©©Ó¾P°Ó30¤Ñªº¿ï¾ÜÅv¡A¥H¬Û¦Pªº±ø´Ú©M±ø¥ó¦b¤½¶}µo°â¤¤ÃB¥~ÁʶR900¸U¬ü¤¸ªº¬ü°ê¦s°U¾ÌÃÒ¡C²£«~¤¤±N¥X°âªº©Ò¦³ADS±N¥ÑASLAN´£¨Ñ¡Cn¬ù¨ü¥«³õ±ø¥óªº¬ù§ô¡AµLªk«OÃÒ¬O§_©Î¦ó®É§¹¦¨n¬ù¡A¤]¤£«OÃÒn¬ùªº¹ê»Ú³W¼Ò©Î±ø´Ú¡C
ASLAN¹wp±N§Q¥Î¦¹¦¸µo¦æªº²b¦¬¯q¤Î¨ä²{¦³ªº²{ª÷©M²{ª÷µ¥»ùª«¡A¥Dn¥Î©ó¸ê§U¨äp¹º¤¤ªº¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢±wªÌªºASLAN004 2b´Á¾¯¶q½d³òµo²{¸ÕÅç¡C ASLANÁÙ¥²¶·ÀvÁÙ¥»¦¸µo¦æ¤¤ªº225¸U¬ü¤¸¥»ª÷¥H¤ÎÀ³©ó2019¦~10¤ë©M2019¦~11¤ëñqªº¶U´Ú¦w±Æ¤UªºÀ³p©M¥¼¥I§Q®§¡C©Ò±o´Ú¶µ²bÃBªº¨ä¾l³¡¤À¡]¦p¦³¡^±N¥Î©ó¸ê§U·sªº©M¨ä¥L¥¿¦b¶i¦æªº¬ãµo¬¡°Ê¡AÀç¹B¸êª÷©M¨ä¥L¤@¯ë¤½¥q¥Î³~¡C
Jefferies LLC©MPiper Sandler¡®Co.¾á¥ô¸Ó²£«~ªºÁp¦X½ãïºÞ²z¤H¡C
¤WzÃÒ¨é¥ÑASLAN®Ú¾ÚF-3ªí®æ¤Wªº³f¬[µn°OÁn©ú¡]¥]¬A°ò¥»©ÛªÑ»¡©ú®Ñ¡^´£¨Ñ¡A¸ÓÁn©ú¥ý«e¥ÑASLAN´£¥æµ¹¬ü°êÃÒ¨é¥æ©ö©eû·|¡]¡§ SEC¡¨¡^¡A¨Ã©ó2009¦~«Å¥¬¥Í®Ä¡C 2021¦~2¤ë11¤é¡A»P¦¹¦¸µo¦æ¦³Ãöªºªì¨B©ÛªÑ»¡©ú®Ñ¸É¥R¸ê®Æ©MÀHªþªº©ÛªÑ»¡©ú®Ñ±N´£¥æµ¹SEC¡A¨Ã¥i¦bSECºô¯¸www.sec.gov¤W§K¶OÀò±o¡C¦b¶i¦æ§ë¸ê¤§«e¡A±zÀ³¸Ó¾\Ūªì¨B©ÛªÑ»¡©ú®Ñ¸É¥R¸ê®Æ¥H¤ÎÀHªþªº©ÛªÑ»¡©ú®Ñ¥H¤Î§Ṳ́w¦VSEC´£¥æªº¨ä¥L¤å¥ó¡A¥HÀò¨ú¦³Ãö§ÚÌ©M¥»²£«~ªº§ó§¹¾ã«H®§¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤W¤È 06:41:57
²Ä 3810 ½g¦^À³
|
©MDupilumab ¤ñ ¦]¸sÅé®t²§¥i¯à¸û¤j¡A¤£¥iª½±µ¤ñ¸û¡C
¦ý¥ÑASLAN004©M¸sÅé¬ÛªñªºLebrikizumab ESAI-90%°ª¥X25%¦Ó¨¥¡AASLAN004ªºADÀø®Ä>=Dupilumab 预´ú§ó¥[½T»{¡C
ASLAN004 ¦bESAI-50%/75%,¦ô¤ñLebrikizumab°ª¥X10%¡B(89%/81%)¤Î(67%/66%) ¦Ó¦bESAI-90% 56%/44%=125%¤ñLebrikizumab°ª¥X25%
¥¼¨Ó©ñ¤j¤H±Ñ¤Î©Ôªø¨ì16¶gªºªvÀø¡A¥u·|¼W¥[®t²§ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤W¤È 05:56:05
²Ä 3809 ½g¦^À³
|
ASLAN004 ¦bESAI-50%/75%,¦ô¤ñLebrikizumab°ª¥X10%¡B(89%/81%)¤Î(67%/66%) ¦Ó¦bESAI-90% 56%/44%=125%¤ñLebrikizumab°ª¥X25%
¥¼¨Ó©ñ¤j¤H±Ñ¤Î©Ôªø¨ì16¶gªºªvÀø¡A¥u·|¼W¥[®t²§
¡K¡K¡K¡K¡K¡K ASLAN004 ¥»¦¸©Û¶Ò¤§°ò½u¸sÅéÀ³¸Ó¤ñ¸û±µªñLebrikizumab 2b ¤¤-««×AD
¦b²Ä8¶g®É¡AªvÀø¾¯¶q¡]400mg©M600mg¶¤¦C¡^ªºEASI¥§¡°§C¶q¬°74¢H¡]n = 9¡^¡A¦Ó¨Ï¥Î¦w¼¢¾¯ªº±wªÌ¬°42¢H¡]n = 5¡^¡C
◦89¢Hªº¤H¹F¨ìEASI-50¡A¦Ó¦w¼¢¾¯¹F¨ì40¢H¡F
◦EASI-75¹F¨ì67¢H¡A¦Ó¦w¼¢¾¯¹F¨ì0¢H¡F
◦EASI-90¹F¨ì56¢H¡A¦Ó¦w¼¢¾¯¹F¨ì0¢H¡C
•22¢Hªº±wªÌ¦bªvÀø¾¯¶q¤UÀò±oªºIGA¬°0©Î1¡A¦Ó¦w¼¢¾¯¬°0¢H¡C
•¶È¥Î¤@¾¯´N¥i§ïµ½®pÈæ±Äo¡A¨Ã¥B¦b8¶g®É¬Û¹ï©ó°ò½u¥§¡«ùÄò§ïµ½46¢H¡A¦Ó¨Ï¥Î¦w¼¢¾¯ªº±wªÌ«h¬°16¢H¡C
•¦bªvÀø²Õ©M¦w¼¢¾¯²Õ¤¤¡Aµo¥Í¤£¨}¨Æ¥ó©M»PªvÀø¬ÛÃöªº¤£¨}¨Æ¥óªº±wªÌ¤ñ¨Ò¬Û¦ü¡C
------------------------- Lebrikizumab 2b ¤¤-««×AD Á{§Éªº«ü¼Ð(2019/3¤ë¤½¥¬)
(¤@).250 mg Q2W(¨â¶g¤@°w) EASI-50 81.0%*** EASI-75 60.6%*** EASI-90 44.0%*** IGA0/1 44.6%**
(¤G).250 mg Q4W(¥|¶g¤@°w) EASI-50 77.0%** EASI-75 56.1%** EASI-90 36.1%** IGA0/1 33.7%*
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 45.8% EASI-75 24.3% EASI-90 11.4% IGA0/1 15.3%
*p<0.05, **p<0.01, and ***p<0.001 versus placebo www.businesswire.com/news/home/20191017005896/en/Dermira-Presents-Data-Phase-2b-Study-Lebrikizumab
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤W¤È 05:15:23
²Ä 3808 ½g¦^À³
|
2.ESAI-90%
dupilumab trial1/trial2 36%/30% vs ¹ï·Ó²Õ 8%/7% dupilumab¡Ï丅CS(¥~¥ÎÃþ©T¾J) trial3 40% vs ¹ï·Ó²Õ 11%
¥[TCS额¥~¼W¥[ªºÀø®Ä¶È1%/6% 3.IGA 0/1 dupilumab trial1/trial2 38%/36% vs ¹ï·Ó²Õ 10%/9% dupilumab¡Ï丅CS(¥~¥ÎÃþ©T¾J) trial3 39% vs ¹ï·Ó²Õ 12%
¥[TCSÃB¥~¼W¥[ªºÀø®Ä¶È1%/0%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤W¤È 04:58:05
²Ä 3807 ½g¦^À³
|
Dupilumab AD ¤T´Á
Dupilumab+TCS(¥~¥ÎÃþ©T¾J¨Å»I) trial3 Àø®Ä«ü¼Ð¹êÅç¹êÅç组ESAI-75% =69%¡K¡K(1) ¹ï·Ó组ESAI-75% =23%¡K¡K(4) (1)-(4)=46%¡K¡K(7)
Dupilumab trial 1 ¹êÅç组ESAI-75%=51%¡K¡K(2) ¹ï·Ó组ESAI-75%=15%¡K¡K(5) (2)-(5)=36%¡K¡K(8)
Dupilumab trial 2 ¹êÅç组ESAI-75%=44%¡K¡K(3) ¹ï·Ó组ESAI-71%=12%¡K¡K(6) (3)-(6)=32%¡K¡K(9)
(7)-(8)=10%¡K¡K¡K¡KTCSªº额¥~Àø®Ä (7)-(9)=14%¡K¡K¡K¡KTCSªº额¥~Àø®Ä
ASLAN004 ESAI-75%=67%Y+TCS 10%-14% =¥i§ïµ½77%-81%
¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K¡K Dupilumab FDA ¼ÐÅÒÀÉ
www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf p.15 3Ó¤T´ÁÁ{§Éx16¶gx2¶g¤@°w Trial1 N=224 :224 Trial2 N=233:236 Trial3 N=106:315
Àø®Ä«ü¼Ð ¡X¡X¡X¡X¡X- 1.ESAI-75%¡C
dupilumab trial1/trial2 51%/44% vs ¹ï·Ó²Õ 15%/12% dupilumab¡Ï丅CS(¥~¥ÎÃþ©T¾J) trial3 69% vs ¹ï·Ó²Õ 23%
2.ESAI-90%
dupilumab trial1/trial2 36%/30% vs ¹ï·Ó²Õ 8%/7% dupilumab¡Ï丅CS(¥~¥ÎÃþ©T¾J) trial3 40% vs ¹ï·Ó²Õ 11%
3.IGA 0/1 dupilumab trial1/trial2 38%/36% vs ¹ï·Ó²Õ 10%/9% dupilumab¡Ï丅CS(¥~¥ÎÃþ©T¾J) trial3 39% vs ¹ï·Ó²Õ 12%
¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦X¤@ªºFB825 ¡ÏTCS , 12¦ì IV ,¤G°w/12¶g
ESAI-75%. 67% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/2 ¤W¤È 01:21:05
²Ä 3806 ½g¦^À³
|
Àø®Ä¤Î¦w¥þ²Ä¤@
¦¹¦¸ESAI-75% ¤ÎESAI-90%
¥¼¨Ó¤T´ÁÀø®Ä«ü¼Ð¡A¤Óº}«G
¤S¦w¥þ¡C®É¶¡¥i¦¬µu¤@¥bªvÀø®É¶¡
¤½¥q©ÒºÙ³Ì¨ÎAD¤Îý³Ý·sÃĬO¯uªº¡C
¥¼¨Ó2bnÅçÃÒ¤G¶g¤@°w/¥|¶g¤@°wx16¶gªº¼Ð·ÇÀøªk¡C
¨üC0VID19¨î¦Ó¤¤断ªº3¦ì¡A¥i¯à¬O200mg组¡C
©Ò¥H¥»¦¸¥¼¤½¥¬¡C
600mg¯uªº¬O¥D¤O¡I
¨ä¥L¥æ给¤½¥q¡C
ªÑ»ù¥«È¤~3»õ¬ü¤¸¡AÂ÷30»õ¬ü¤¸ªº¥Ø«e³Q¨ÖÁÊ»ùÈ¡A®t900% ¥«³õ·|ÁÙ´Á¤½¹D¡A¨È狮»Ý¦A©M¥«³õ·¾³q¡CÅý»ùȳsµ²ªÑ»ù¡C
¦w¤ßºÎı¡I
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G»Û£Âû´ö10151217 |
µoªí®É¶¡:2021/3/2 ¤W¤È 12:47:59
²Ä 3805 ½g¦^À³
|
ÁÂÁ¦U¦ì¤j¤jªº¤À¨É µ¹¨¬¤Fº¡º¡ªº«H¤ß µ¥³o»ò¤[¤F ¬Û«H¨È·à·|·U¨Ó·U¦nªº §Æ±æ¤µ¤ÑªÑ»ù¦¬ªºº}«G!!!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/1 ¤U¤È 11:56:11
²Ä 3804 ½g¦^À³
|
¥»¦¸´Á¤¤¼Æ¾Ú¥u¤½§i18¤H¤¤ªº9¤H¡AÆ[¹î8¶gªº¼Æ¾Ú¡ADupilumab ¤T´Á¬OÆ[¹î12¶g¡AÂå¾Çªø´£¨ì¦~¤¤·|¤½§i§¹¾ã¬ù50¤Hªº¼Æ¾Ú¡C Ó¤H»{¬°±Ú¸sÂX¼W¦³18¤H¬O¥Î600mg,¥[¤W쥻400mg,600mgÆ[¹î®É¶¡©Ôªø¡A¼Æ¾Ú¬O§_·|§ó«G²´¡A¤½§i«á´N·|§ó¾é¸Ñ¨ä¼ç¤O»ùÈ¡C ¤µ¤Ñ¥u¬OºÝ¥X¤pµæ¡A¤jµæ¦b«á¡C ¥H¤W¤À¨É¡A¶È¨Ñ°Ñ¦Ò
www.globenewswire.com/fr/news-release/2021/03/01/2184010/0/en/ASLAN-Pharmaceuticals-Announces-Positive-Interim-Data-From-the-Multiple-Ascending-Dose-Study-of-ASLAN004-in-Atopic-Dermatitis.html
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§d½n¶¯10142119 |
µoªí®É¶¡:2021/3/1 ¤U¤È 11:28:30
²Ä 3803 ½g¦^À³
|
¬Û«H¼Æ¾Ú¡A´N©ñµÛ... ¼Æ¾Ú¤~¬O¤ý¹D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©ú¤Ñ¹L«á10151242 |
µoªí®É¶¡:2021/3/1 ¤U¤È 11:10:53
²Ä 3802 ½g¦^À³
|
¶}°ª¨«§C¬OALSNªº±j¶µ,¦pªG¤£¬O¥h¦~§CÂI¶R¤Jªº¤H®Ú¥»©ê¤£¦í,¨Ò¦p¤µ¤Ñ¶}½L¶R¤J6.5ªº²{¦b´N·|±þ¥X»{½ß5.5..... Á`¤§¦ª¾¹Dªº¤H¤]¥¬§½§¹²¦¤F,µu½uªº°ª§CÂI´N¤£¥Î¥h²z·|¤F....«Øij¥xÆW§ë¸êªÌÄ~Äò¾Ö©ê.... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¹ÚµM10150107 |
µoªí®É¶¡:2021/3/1 ¤U¤È 10:56:01
²Ä 3801 ½g¦^À³
|
§Ô¦í.²×©óÀò§Q¡B¤@ª½¦³Àò§Qªº½Ä°Ê |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2021/3/1 ¤U¤È 10:49:29
²Ä 3800 ½g¦^À³
|
¼Æ¾ÚªGµMÅåÆv¡A°O±oªÑ²¼Âê°_¨Ó¡A§â¤â¸j°_¨Ó¡A¤£n¶Ã½æ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/1 ¤U¤È 09:59:32
²Ä 3799 ½g¦^À³
|
Dupilumab FDA ¼ÐÅÒÀÉ
www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf p.15 3Ó¤T´ÁÁ{§Éx16¶gx2¶g¤@°w Trial1 N=224 :224 Trial2 N=233:236 Trial3 N=106:315
Àø®Ä«ü¼Ð ¡X¡X¡X¡X¡X- 1.ESAI-75%¡C
dupilumab trial1/trial2 51%/44% vs ¹ï·Ó²Õ 15%/12% dupilumab¡Ï丅CS(¥~¥ÎÃþ©T¾J) trial3 69% vs ¹ï·Ó²Õ 23%
2.ESAI-90%
dupilumab trial1/trial2 36%/30% vs ¹ï·Ó²Õ 8%/7% dupilumab¡Ï丅CS(¥~¥ÎÃþ©T¾J) trial3 40% vs ¹ï·Ó²Õ 11%
3.IGA 0/1 dupilumab trial1/trial2 38%/36% vs ¹ï·Ó²Õ 10%/9% dupilumab¡Ï丅CS(¥~¥ÎÃþ©T¾J) trial3 39% vs ¹ï·Ó²Õ 12%
¡X¡X¡X¡X¡X¡X¡X¡X¡X ¦X¤@ªºFB825 ¡ÏTCS , 12¦ì IV ,¤G°w/12¶g
ESAI-75%. 67% |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Gellelin10138869 |
µoªí®É¶¡:2021/3/1 ¤U¤È 09:34:19
²Ä 3798 ½g¦^À³
|
«Ó°¶¤j¡A§Ú·íªì¤]³Q¯º¡A§Ú·Q³o¶¥¬q·à¤Í̳£¨«¹L¡I ¦p¤µ¡A®¢¯º§Ú̪º¤H¥Í¬¡¨Ã¨S§ïÅÜ¡A ¦ý§ÚÌ«o¤j¤j¤£¦P¤F¡I ¥t¥~¡A ¼Æ¾Ú¦n¡A¤ñ»ù¦X¤@¤£¹L¥÷§a😜 §Æ±æ¶}½L«á©µÄò½L«e®ð¶Õ¡A¶}°ª¦¬§ó°ª¡I ¤µ±ß¤Ó¶Ù¤F¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/1 ¤U¤È 09:31:37
²Ä 3797 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/1 ¤U¤È 09:22:32
²Ä 3796 ½g¦^À³
|
¼Æ¾Ú¶W¦n ¬Ý½L«e·à¤lADRªº®ð¶Õ ¤µ¦~¦³¾÷·|º¦¤@¿¥H¤W ·P°Ê¡A±q§ë¸ê¤j½ß³Q¯ºÅܦ¨¤jÁȤF ®¥³ß¼õ¹L¨Óªº¤j®a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/1 ¤U¤È 08:39:50
²Ä 3795 ½g¦^À³
|
ASLAN004 ¥»¦¸©Û¶Ò¤§°ò½u¸sÅéÀ³¸Ó¤ñ¸û±µªñLebrikizumab 2b ¤¤-««×AD
¦b²Ä8¶g®É¡AªvÀø¾¯¶q¡]400mg©M600mg¶¤¦C¡^ªºEASI¥§¡°§C¶q¬°74¢H¡]n = 9¡^¡A¦Ó¨Ï¥Î¦w¼¢¾¯ªº±wªÌ¬°42¢H¡]n = 5¡^¡C
◦89¢Hªº¤H¹F¨ìEASI-50¡A¦Ó¦w¼¢¾¯¹F¨ì40¢H¡F
◦EASI-75¹F¨ì67¢H¡A¦Ó¦w¼¢¾¯¹F¨ì0¢H¡F
◦EASI-90¹F¨ì56¢H¡A¦Ó¦w¼¢¾¯¹F¨ì0¢H¡C
•22¢Hªº±wªÌ¦bªvÀø¾¯¶q¤UÀò±oªºIGA¬°0©Î1¡A¦Ó¦w¼¢¾¯¬°0¢H¡C
•¶È¥Î¤@¾¯´N¥i§ïµ½®pÈæ±Äo¡A¨Ã¥B¦b8¶g®É¬Û¹ï©ó°ò½u¥§¡«ùÄò§ïµ½46¢H¡A¦Ó¨Ï¥Î¦w¼¢¾¯ªº±wªÌ«h¬°16¢H¡C
•¦bªvÀø²Õ©M¦w¼¢¾¯²Õ¤¤¡Aµo¥Í¤£¨}¨Æ¥ó©M»PªvÀø¬ÛÃöªº¤£¨}¨Æ¥óªº±wªÌ¤ñ¨Ò¬Û¦ü¡C
------------------------- Lebrikizumab 2b ¤¤-««×AD Á{§Éªº«ü¼Ð(2019/3¤ë¤½¥¬)
(¤@).250 mg Q2W(¨â¶g¤@°w) EASI-50 81.0%*** EASI-75 60.6%*** EASI-90 44.0%*** IGA0/1 44.6%**
(¤G).250 mg Q4W(¥|¶g¤@°w) EASI-50 77.0%** EASI-75 56.1%** EASI-90 36.1%** IGA0/1 33.7%*
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 45.8% EASI-75 24.3% EASI-90 11.4% IGA0/1 15.3%
*p<0.05, **p<0.01, and ***p<0.001 versus placebo www.businesswire.com/news/home/20191017005896/en/Dermira-Presents-Data-Phase-2b-Study-Lebrikizumab |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªÅÄ_10148533 |
µoªí®É¶¡:2021/3/1 ¤U¤È 08:23:16
²Ä 3794 ½g¦^À³
|
¬Ý¨£¨È·à±dªº»ùÈ ¨£ÃѬüªÑªº´A¤O
ÁÂÁ¤ѩR¤j¤jªºµL¨p¤À¨É |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/1 ¤U¤È 08:16:06
²Ä 3793 ½g¦^À³
|
¤T´ÁÁ{§É¥Dn«ü¼Ð¬°¼Æ(1)/(2)
¦b²Ä¤K¶g´N¦³¦p¦¹¦¨¿¦,®¥³ß¤j®a
(1)EASI-75¹F¨ì67¢H¡A¦Ó¦w¼¢¾¯¹F¨ì0¢H¡F
(2)22¢Hªº±wªÌ¦bªvÀø¾¯¶q¤UÀò±oªºIGA¬°0©Î1¡A¦Ó¦w¼¢¾¯¬°0¢H¡C
◦EASI-90¹F¨ì56¢H¡A¦Ó¦w¼¢¾¯¹F¨ì0¢H¡C
----------------- DUPILUMAB ¤T´Á 16¶g
ESAI-90% ¤ñ IGA ,0/1§C¬O¥¿±`.
°ò½uªºIGA ¦b4 ªÌ 47%~49%
©Ò¥H75%ESAI ´N¦³¾÷·|¦¨¬°IGA ,0/1
¥»¦¸ASLAN004 ´Á¤¤◦EASI-90¹F¨ì56¢H,¯uªº¥i³ß,¥i¶P.
22¢Hªº±wªÌ¦bªvÀø¾¯¶q¤UÀò±oªºIGA¬°0©Î1 ------- -¤é«áÁ{§É200¤H¼Æ®É¥²¤ÏÀ³¤ñ²v°ª©óEASI-90¹F¨ì56¢H
----------------- 2.1Dupliumab 3´Á ¤¤-««×AD, 2ÓSOLO1/SOLO2 Á{§Éªº«ü¼Ð(2016¦~¤½¥¬)
(¤@).300 mg Q2W(¨â¶g¤@°w/16¶g) EASI-50 65%/69% EASI-75 51%/44% EASI-90 36%/30% IGA0/1 38%/36%
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 25%/22% EASI-75 15%/12% EASI-90 8%/7% IGA0/1 10%/8%
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GPica10150664 |
µoªí®É¶¡:2021/3/1 ¤U¤È 07:49:25
²Ä 3792 ½g¦^À³
|
ÁÂÁ¤ѩR¤jªº¤@¸ô¤À¨É¡A²×©óµ¥¨ì³o¤@¨è¡A ªÑ²¼Âê¦b¥xÆWªº§Ú¡A·|³µÛ¤j®aÄ~Äò©ê¤U¥h¡C --------------------------------------------------------------------- ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2021/3/1 ¤U¤È 07:16:47²Ä 3789 ½g¦^À³ ¸Ñª¼¤F
¼Æ¾Ú¶Wº}«G |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/1 ¤U¤È 07:46:45
²Ä 3791 ½g¦^À³
|
2021¦~3¤ë1¤é
ASLAN Pharmaceuticals«Å¥¬²§¦ì©Ê¥Öª¢ªºASLAN004¦h¦¸¤É¾¯¶q¬ã¨sÀò±o¤F¥¿¦Vªº¤¤´Á¼Æ¾Ú
-8¶g«á¡AªvÀø¾¯¶qªºEASI¥§¡¸û°ò½u°§C74¢H¡C
89¢Hªº±wªÌ¹F¨ìEASI-50¡A56¢Hªº±wªÌ¹F¨ìEASI-90
-¼Æ¾Ú¤ä«ùASLAN004§@¬°°w¹ïIL-13Rªº FIRST-IN-CLASS §ÜÅ骺¼ç¤O¡A¦b²§¦ì©Ê¥Öª¢¤¤¨ã¦³¿W¯Sªº¥\®Ä©M¦w¥þ©Ê
-ºÞ²z¼h±N©ó3¤ë1¤é¬ü°êªF³¡®É¶¡¤W¤È8ÂI/¬ü°ê¼Ð·Ç®É¶¡±ß¤W9ÂI¥D«ù¹q¸Ü·|ij©Mºôµ¸¼s¼½
2021¦~3¤ë1¤é¡A·s¥[©Y¡A·s¥[©Y-¥þ²y»â¥ýªº¥HÁ{§É¶¥¬q§K¬Ì¾Ç¬°°ò¦ªº¥Íª«»sÃĤ½¥qASLAN Pharmaceuticals¡]¯Ç´µ¹F§JªÑ²¼¥N½X¡GASLN¡^¥¿¦b¶}µo³Ð·sÀøªk¥H§ïÅܱwªÌªº¥Í¬¡¡A
¤µ¤Ñ«Å¥¬¤F¨Ó¦Û¥H¤U¤TÓ¾¯¶q²Õªº¥¿¦V¸Ñª¼¼Æ¾Ú¶i¦æ¤¤ªº ASLAN004ÀH¾÷¡AÂùª¼¦w¼¢¾¯¹ï·Ó¦h¾¯¶q»¼¼W¬ã¨s¡A¥Î©óªvÀø¤¤«×¦Ü««×¯SÀ³©Ê¥Öª¢¡]AD¡^¡C
¤wÅã¥ÜASLAN004¦b©Ò¦³¾¯¶q¤U§¡¨ã¦³¨}¦nªº@¨ü©Ê¡A¨Ã¥B¦b©Ò¦³¥\®Ä²×ÂI§¡Åã¥Ü¥X»P¦w¼¢¾¯¬Û¤ñ¦³©Ò§ïµ½¡A±q¦Ó¤ä«ù¤F¨ä§@¬°AD®t²§¤Æ¡A·s¿oªvÀøªº¼ç¤O¡C
1´Á¬ã¨sµû¦ô¤F¥Ö¤U»¼°eªº¤T¾¯ASLAN004¡]200mg¡A400mg©M600mg¡^¡A²{¦b¥¿¦b©Û¶Ò²Ä¥|§å¡]ÂX®i¡^±wªÌ¡]600mg¡^¡C ¨C¶g¹ï±wªÌµ¹ÃĤK¶g¡A¥H½T©wASLAN004ªº¦w¥þ©Ê©M@¨ü©Ê¥H¤Î³\¦h¦¸nÀø®Ä«ü¼Ð¡C «e¤TÓ¶¤¦C±N¨Ó¦Û¬ü°ê¡A¿D¤j§Q¨È©M·s¥[©Yªº25¦W±wªÌÀH¾÷¤À²Õ¡C¥Ñ©ó¹ïCOVID-19ªº¤ÏÀ³¬I¥[¤F¨î¡A¤T¦W±wªÌ¤¤¤î¤F¬ã¨s¡C ¦b¨ä¾lªº22¦ì±wªÌ¤¤¡A¦³18¦ì¦Ü¤Ö§¹¦¨¤F29¤Ñªºµ¹ÃÄ©Mµû¦ô¡A¨Ã¥B¥i¥Hµû¦ôÀø®Ä
•±wªÌªº¥§¡°ò½uÀã¯l±¿nÄY«©Ê«ü¼Æ¡]EASI¡^±o¤À¬°32.5¡A¬ã¨sªÌ¥þ²yµû¦ô¡]IGA¡^ªº¥§¡±o¤À¬°3.4¡]n = 18¡^¡C
•¦b²Ä8¶g®É¡AªvÀø¾¯¶q¡]400mg©M600mg¶¤¦C¡^ªºEASI¥§¡°§C¶q¬°74¢H¡]n = 9¡^¡A¦Ó¨Ï¥Î¦w¼¢¾¯ªº±wªÌ¬°42¢H¡]n = 5¡^¡C
◦89¢Hªº¤H¹F¨ìEASI-50¡A¦Ó¦w¼¢¾¯¹F¨ì40¢H¡F
◦EASI-75¹F¨ì67¢H¡A¦Ó¦w¼¢¾¯¹F¨ì0¢H¡F
◦EASI-90¹F¨ì56¢H¡A¦Ó¦w¼¢¾¯¹F¨ì0¢H¡C
•22¢Hªº±wªÌ¦bªvÀø¾¯¶q¤UÀò±oªºIGA¬°0©Î1¡A¦Ó¦w¼¢¾¯¬°0¢H¡C
•¶È¥Î¤@¾¯´N¥i§ïµ½®pÈæ±Äo¡A¨Ã¥B¦b8¶g®É¬Û¹ï©ó°ò½u¥§¡«ùÄò§ïµ½46¢H¡A¦Ó¨Ï¥Î¦w¼¢¾¯ªº±wªÌ«h¬°16¢H¡C
•¦bªvÀø²Õ©M¦w¼¢¾¯²Õ¤¤¡Aµo¥Í¤£¨}¨Æ¥ó©M»PªvÀø¬ÛÃöªº¤£¨}¨Æ¥óªº±wªÌ¤ñ¨Ò¬Û¦ü¡C
¥D°ÊÁu¤¤¨S¦³»PªvÀø¬ÛÃöªº¤£¨}¨Æ¥ó¾ÉP°±ÃÄ¡C
ASLAN Pharmaceuticalsº®uÂå¾Ç©xKen Kobayashi³Õ¤hµû½×»¡¡G¡§³o¨Ç¼Æ¾Ú¥O¤H¹ª»R¡A¨Ã¬°¦Û«H¦a±À¶i§ÚÌp¹º©ó¤µ¦~±ß¨Ç®ÉԱҰʪº¥þ²y2b´Á¬ã¨sp¹º´£¨Ñ¤F°í¹êªº°ò¦¡C
ASLAN004ªºÃ°·¥B»P²³¤£¦Pªº¦w¥þ©Ê©M¦³®Ä©Ê·§ªp¥¿¦b¥X²{¡A§ÚÌ´Á«Ý¦b2021¦~¤¤´Á³ø§i¬ù50¦W±wªÌªº§¹¾ã¡A¸Ñª¼¼Æ¾Ú¡C
§Ú̬۫H¡A¤¤´Á¼Æ¾Úªí©úASLAN004¨ã¦³°w¹ïIL-13¨üÅ骺¤@¬yÀøªkªº¼ç¤O¡A¨Ã¨ã¦³®t²§¤Æªº¤èªk¨ÓªvÀø¯SÀ³©Ê¥Öª¢¡C¡¨
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/1 ¤U¤È 07:25:03
²Ä 3790 ½g¦^À³
|
¤½¥q·s»D½Z
Mar 01,2021
ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis
- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90
- Data supportive of ASLAN004¡¦s potential as a novel, first-in-class antibody targeting IL-13R with differentiated efficacy and safety profile in atopic dermatitis
- Management to host conference call and webcast today, 1 March, at 8am ET / 9pm SGT
SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced positive interim unblinded data from the three dose cohorts of its ongoing randomised, double-blind placebo controlled multiple ascending dose study of ASLAN004 for the treatment of moderate to severe atopic dermatitis (AD). ASLAN004 was shown to be well tolerated across all doses and showed improvements compared to placebo in all efficacy endpoints, supporting its potential as a differentiated, novel treatment for AD.
The Phase 1 study evaluated three doses of ASLAN004 (200mg, 400mg and 600mg) delivered subcutaneously and is now recruiting a fourth (expansion) cohort (600mg). Patients were dosed weekly for eight weeks to determine the safety and tolerability of ASLAN004 as well as a number of secondary efficacy outcome measures. The first three cohorts randomised 25 patients from the United States, Australia and Singapore. Three patients discontinued study due to restrictions imposed in response to COVID-19. Of the remaining 22 patients, 18 completed at least 29 days of dosing and assessment and were evaluable for efficacy. •The average baseline Eczema Area Severity Index (EASI) score of patients was 32.5 and the average Investigators Global Assessment (IGA) score was 3.4 (n=18). •At week 8, the average reduction in EASI from baseline at therapeutic doses (400mg and 600mg cohorts) was 74% (n=9) compared to 42% (n=5) for patients on placebo.
◦89% achieved EASI-50 versus 40% on placebo; ◦67% achieved EASI-75 versus 0% on placebo; ◦56% achieved EASI-90 versus 0% on placebo.
•22% of patients achieved IGA of 0 or 1 at therapeutic doses versus 0% on placebo. •Peak pruritus improved after just one dose and continued to improve by an average of 46% relative to baseline at 8 weeks compared to 16% for patients on placebo. •The proportion of patients with adverse events and treatment-related adverse events were similar across treatment and placebo arms. There were no treatment-related adverse events in the active arm that led to discontinuation.
Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, commented: ¡§These data are very encouraging and provide a strong foundation to confidently advance our plans for the global Phase 2b study we intend to initiate later this year. A robust and differentiated safety and efficacy profile is emerging for ASLAN004 and we look forward to reporting the full, unblinded data from approximately 50 patients in mid-2021. We believe the interim data demonstrate ASLAN004¡¦s potential as a first-in-class therapeutic targeting the IL-13 receptor with a differentiated approach to treating atopic dermatitis.¡¨
Conference call and webcast
ASLAN¡¦s management will host a webcast and conference call at 8am ET / 9pm SGT today, 1 March 2021, to discuss these interim data. The live call may be accessed by dialing +1 855 548 1217 for domestic callers and +1 409 217 8810 for international callers and entering the conference code: 9199389. A live webcast of the call will be available using this link: edge.media-server.com/mmc/p/o2mdjnyx. It will also be available from the News and Events page of the Company¡¦s website at ir.aslanpharma.com/webcasts-presentations and will be archived there after the live event. ir.aslanpharma.com/news-releases/news-release-details/aslan-pharmaceuticals-announces-positive-interim-data-multiple |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/1 ¤U¤È 07:16:47
²Ä 3789 ½g¦^À³
|
¸Ñª¼¤F
¼Æ¾Ú¶Wº}«G
ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis
© Reuters.
- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90
- Data supportive of ASLAN004¡¦s potential as a novel, first-in-class antibody targeting IL-13R with differentiated efficacy and safety profile in atopic dermatitis
- Management to host conference call and webcast today, 1 March, at 8am ET / 9pm SGT
SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced positive interim unblinded data from the three dose cohorts of its ongoing randomised, double-blind placebo controlled multiple ascending dose study of ASLAN004 for the treatment of moderate to severe atopic dermatitis (AD). ASLAN004 was shown to be well tolerated across all doses and showed improvements compared to placebo in all efficacy endpoints, supporting its potential as a differentiated, novel treatment for AD.
The Phase 1 study evaluated three doses of ASLAN004 (200mg, 400mg and 600mg) delivered subcutaneously and is now recruiting a fourth (expansion) cohort (600mg). Patients were dosed weekly for eight weeks to determine the safety and tolerability of ASLAN004 as well as a number of secondary efficacy outcome measures. The first three cohorts randomised 25 patients from the United States, Australia and Singapore. Three patients discontinued study due to restrictions imposed in response to COVID-19. Of the remaining 22 patients, 18 completed at least 29 days of dosing and assessment and were evaluable for efficacy. The average baseline Eczema Area Severity Index (EASI) score of patients was 32.5 and the average Investigators Global Assessment (IGA) score was 3.4 (n=18). At week 8, the average reduction in EASI from baseline at therapeutic doses (400mg and 600mg cohorts) was 74% (n=9) compared to 42% (n=5) for patients on placebo. 89% achieved EASI-50 versus 40% on placebo; 67% achieved EASI-75 versus 0% on placebo; 56% achieved EASI-90 versus 0% on placebo. 22% of patients achieved IGA of 0 or 1 at therapeutic doses versus 0% on placebo. Peak pruritus improved after just one dose and continued to improve ...
Full story available on Benzinga.com
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/1 ¤U¤È 04:10:41
²Ä 3788 ½g¦^À³
|
¤@.AD¥Íª«»s¾¯¥«³õ:2027¦~¥þ²y¦ô210»õ¬ü¤¸(¬ü°ê72%/¼Ú¬w25%/¤é¥»3%)
Dupilumab ¾P°â°ªÂI;±N¹F110»õ¬ü¤¸.ªÑ²¼¥«³õ2020¦~«e¥b¦~µ¹¤©300»õ¬ü¤¸ªº¼WÈ.
¤G.2019/DEC/02 ¤½¥¬¤TÓAslan004 ,1b¼Æ¾Ú EASI °§C 85%/70%/59%,¥§¡71% ,¯à§i¶D§Ṳ́°»ò¸ê°T?
1.¥i¹w§P ¥¼¨ÓASLAN004 ¤T´ÁÁ{§É¥²¹LÃö,(¹êÅç²Õ vs ¹ï·Ó²Õ/¥DnÀø®Ä«ü¼Ð¤ñ IGA 0/1 380%~450% )
³oºØ¼Æ¾Ú¦b¤H¼Æ©ñ¤j¨ì¤T´ÁÁ{§É 400¤H(266:133) , P¡Õ0.000001 ,
¤T´ÁÁ{§É¹êÅç²Õ°ª¹ï·Ó²Õ66%¡Ap<0.01´N¹LÃö¡C
2¡B¥i±æ¦P¯Å³Ì¨Î Dupilumab»PASLAN004 ¯à¦P®ÉªýÂ_IL-4©MIL-13ªº°T¸¹¶Ç¾É ----------------------------------------------------------- ¨ä¥LÃĪ«¨Ò¦plebrikizumab©Mtralokinumabµ¥¥u¯àªýÂ_IL-13³æ¦V°T¸¹¶Ç¾É
³Ì¨Î: ¾¯¶q/¥ÎÃÄÀW²v/Àø®ÄIGA 0/1 /Àøµ{¦¨¥»³Ì§C
(1).²z½×/¹ê»Ú¤W: ¥Íª«»s¾¯§@¥Î©ó¨ü¾¹¹v¦ì Àu©ó§@¥Î¨ä¥LIL13°tÅé.
Aslan004 200mg /2~4¶g¤@°w¡H Lerikizumab 250mg/2¶g¤@°w(2019/10¤ë, ¤T´ÁÁ{§É¶}©l) Duilpumab 300mg/2¶g¤@°w(2017¦~3¤ë¤W¥«,,²Ä¤@Ӽйv¤W¥«) Tralokinumab 300mg/2¶g¤@°w(2019/12 ¤T´ÁÁ{§É¹LÃö,¦ýIGA 0/1 »P¹ï·Ó²Õ¤ñÈ2,¶Èdupilumab ¤@¥b)
(2).Aslan004 -¤@´Á°·±d¤HÁ{§É¹êÅçÃÒ¹ê, (A)¾¯¶q³Ì¤Ö¡A1mg/L , ¨C¤½¤É¦å²G1mg ¿@«×§Y¥i§í¨î¡A ¦ÓDupilumab ¥ÎÃÄ600mg °_©l¶q§¹²Ä¤@¶g¥§¡¿@«×70mcg/ml= 70mg/L. ¯S§Oȱoª`·Nªº¬O¡A¸ÕÅç¼Æ¾Ú«ü¥XASLAN004§¹¥þ§í¨î¨ü¾¹°T¸¹¶Ç»¼©Ò»Ýªº³Ì§C¿@«× (trough level)¤ñ²{¦³ªvÀø¤è¦¡©Ò»Ýªº¿@«×§C¡A¿@«×®t¶Z¶W¹L¤@Ӽƶq(10¿)¯Å¡C
(B)¬I¥´ÀW²v³Ì¤Ö¡A¥i±æ¤@¤ë¤@°w¡A
(3).Àø®Ä¬Û·ídupilumab ,Àu©ó¨ä¥L¤GÃÄ
(A). EASI -50 ¼Æ¾Ú PK Aslan004 100% (1b ,n=3) Dupilumab 71.4%/placebo(¹ï·Ó²Õ)18.8% .¡]1b ,n=21:16 )/ 65~69% /placebo 25%~22%(ph3 n=233:233) Lerikizumab 81%(2b 78:52) (B.) EASI 3¤H¥§¡°´T71% ,±µªñ300/¨C¶g¤@°wdupilumab 2a ,²Ä5 ¶g EASI °67%.
¤T¡BÁ`Ävª§¤O: ¦³¼ç¤O§C©óDupilumab30%~60% Àøµ{¦¨¥»¤W¥« ,¥B°Æ§@¥Î§C. ¤½/¨p¥ß«OÀI¤½¥q ¨ÌÀøµ{¦¨¥»¨Ó±¾§Ç¥ÎÃĵ{§Ç.¦¨¥»§Cªº¥ý¥Î.
¥|¡B¹w¦ô·m¤U:50»õ¬ü¤¸¥«³õ ®Ú¾Ú©MCSL¦X¬ù(7.8»õ¬ü¤¸(«eª÷+¨½µ{ª÷)+ 5~10%¾P°â¤À¼í)*2+ ¥«³õÂX¥R «O¦u¦ôp.
¤¡B°ê»Ú¼Ð¹vªvÀø ¤¤-««×²§¦ì©Ê¥Öª¢AD¤§±ÂÅv:
1.2016¦~,LEO Pharma©ó2016¦~±qªü´µ§Q±d¡]LSE¡GAZN¡^Àò±o¤F¥Ö½§¯e¯f¤¤ªºtralokinumabªºÅv§Q¡A¸Ó¥æ©ö¯A¤Î¦V^°ê-·ç¨å»sÃÄ¥¨ÀY¹w¥I1.15»õ¬ü¤¸¡A¥H¤Î°ª¹F10»õ¬ü¤¸ªº°Ó·~¬ÛÃö¨½µ{¸O©M²£«~¾P°âªº¯S³\Åv¨Ï¥Î¶O¤ñ¨Ò¤£¶W¹L¦Ê¤À¤§¤Q
LEO Pharma reveals positive top-line Phase III results for tralokinumab(¤T´ÁADÁ{§É¤w¸Ñª¼¦¨¥\,2019/12 ¤ë) ²Ä¤@ÓÂê©wIL13 °tÅé¤À§OªýÂ_»PIL13¨üÅé¨üÅé£\1¦¸³æ¦ì (¥çºÙ¬°IL-13R£\1) ¤ÎªýÂ_¨üÅé£\2¦¸³æ¦ì (¥çºÙ¬°IL-13R£\2) µ²¦X¡A ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
2.2017/08/08 (2019/10 ¤T´ÁÁ{§É¶}©l) Dermira¦Vù¤óROCHE ,ÁʶR Lebrikizumab¥þ²yAD¶}µoÅv«eª÷8000¸U¬ü¤¸¡A2018¦~¦A¤ä¥I5500¸U¬ü¤¸¡C ±Ò°Ê²Ä¤@Ó3´Á¤§«e¤ä¥I4000¸U¬ü¤¸¡A¦b¬Y¨Ç¦a°Ï¨ú±oÃÄÃÒ©Mº¦¸°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù14»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%. Áô§t28»õ¬ü¤¸³Ì°ª¾P°âÃB.
Âê©wIL13 °tÅ餧¼Ð¹v ¥ØªºªýÂ_IL-13R£\1»P IL-4R£\1¤§°T®§¶Ç»¼¤§¾÷Âà
2.1 , 2019/02 ,Dermira ¦A±Â¥X¼Ú¬wLebrikizumab °Ó·~¤ÆÅv¤Oµ¹Almirall,¤½¥q.
Out-License and Other Agreements Almirall Agreement
2019¦~6¤ë30¤é¬°1.10»õ¬ü¤¸¡A¨½µ{ª÷+¾P°â¨½µ{ª÷?+¾P°â¤À¼í? ¨ä¤¤¥]¬A¡G¡]i¡^3000¸U¬ü¤¸ªº«e´Á´ÁÅv¶O; ¡]ii¡^5,000¸U¬ü¤¸ªº´ÁÅv¦æÅv¶O¡F ¡]iii¡^3000¸U¬ü¤¸ªº¨½µ{¸O
3.2019/05/31 , CSL»P¨È·à2014¦~°_¦@¦P¶}µo,§Q¼í¦U¥b. 1a °µ§¹ CSL ¨È·à¦@¦P±ÂÅvASLAN004 ¥þ²yµo®i/¥Í²£/°Ó·~¤Æµ¹ ¨È·à±d, (±ÂÅvª÷=(«eª÷+¨½µ{ª÷ 1.25»õ¬üª÷ +³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷)*2=7.8*2»õ¬üª÷)+ (¥[¾P°â¤À¼í5%~<= 10%.)*2 ¦U±o¤@¥b.
¨È·à¶RÂ_»ù =±ÂÅvª÷(«eª÷+¨½µ{ª÷ 1.25»õ¬üª÷ +³Ì°ª¹F 6.55 »õ¤§¾P°â¨½µ{ª÷)=7.8»õ¬üª÷)+ (¥[¾P°â¤À¼í5%~<= 10%.)
4.2020/¤¸¤ë ,§¨Ó¨ÖÁÊDermira ¤½¥q/Lebrikizumab
§é²{»ùÈ 29»õ¬ü¤¸.
11»õ¬ü¤¸²{ª÷+ ¤ä¥Iù¤óROCHE Lebrikizumab¥þ²yAD¶}µoÅv,°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%.
§é²{Ȧô 29»õ¬ü¤¸,
5.¤½¥qp¹ºASLAN004 2022¦~°µ2b Á{§É«á±ÂÅv ,¼ç¦b¦X§@¥ë¦ñ2019¦~10¤ë°_,¤w°Ñ»PÁ{§É³]p¤Î±ÂÅv¬ã°Q.
¤».°O¦í©³¤UÁ{§É¼Æ¾Ú¡C
1.Lebrikizumab 2b ¤¤-««×AD Á{§Éªº«ü¼Ð(2019/3¤ë¤½¥¬)
(¤@).250 mg Q2W(¨â¶g¤@°w) EASI-50 81.0%*** EASI-75 60.6%*** EASI-90 44.0%*** IGA0/1 44.6%**
(¤G).250 mg Q4W(¥|¶g¤@°w) EASI-50 77.0%** EASI-75 56.1%** EASI-90 36.1%** IGA0/1 33.7%*
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 45.8% EASI-75 24.3% EASI-90 11.4% IGA0/1 15.3%
*p<0.05, **p<0.01, and ***p<0.001 versus placebo www.businesswire.com/news/home/20191017005896/en/Dermira-Presents-Data-Phase-2b-Study-Lebrikizumab ------------ 2.1Dupliumab 3´Á ¤¤-««×AD, 2ÓSOLO1/SOLO2 Á{§Éªº«ü¼Ð(2016¦~¤½¥¬)
(¤@).300 mg Q2W(¨â¶g¤@°w/16¶g) EASI-50 65%/69% EASI-75 51%/44% EASI-90 36%/30% IGA0/1 38%/36%
(¤T)¹ï·Ó²ÕPlacebo
EASI-50 25%/22% EASI-75 15%/12% EASI-90 8%/7% IGA0/1 10%/8%
www.nejm.org/doi/full/10.1056/NEJMoa1610020?cookieSet=1
2.2 Dupliumab 2b Á{§Éªº«ü¼Ð(2014¦~/7¤ë¤½¥¬)/16¶gªvÀø/n=380 ,6²Õ, (300 mg weekly, 300 mg every other week, 300 mg monthly, 200 mg every other week, 100 mg monthly) or placebo.
300mg/¨C¶g¤@°w, ESAI ¥§¡°74%/vs ¹ï·Ó²Õ¥§¡°18% 100mg/¨C¤ë¤@°w, ESAI ¥§¡°45%
5²Õ¹êÅç²Õpk¹ï·Ó²Õ, P¬Ò <0.0001
www.drugs.com/clinical_trials/regeneron-sanofi-announce-positive-results-phase-2b-study-dupilumab-atopic-dermatitis-16580.html
---------------- 3.---2019/12 ,³q¹L¤T´ÁÁ{§Éªºtralokinumab,--- IGA 0/1 was 19.1% with active therapy versus 8.1% with placebo (P < .001) in ECZTRA 1 24.0% versus 12.4% (P < .001) in ECZTRA 2. For EASI 75, the respective proportions were 33.4% versus 17.3% (P< .01) and 37.9% versus 16.4% (P < .01).
¤C.资°T¤£¹ïºÙ»ùÈ
¬ü¡B¥xªÑ¥«©|¥¼¤ÏÀ³ 1.¨È狮»PCSL¦@¦P¶}µoASLAN004¨ì1aÁ{§É§¹¦¨ªº§Q¯q¡C 2019/05/31¤w¸g°ê»Ú±ÂÅv¡A¨È·à©Ò±o§Q¯q¦ô§é现È10»õ¬ü¤¸¡C¥tCSL¥ç±o10»õ¬ü¤¸ªº¼ç¦b§Q¯q¡A¦@20»õ¬ü¤¸¡C ñ约°ò¦¡A°Ñ¦Ò°ê»Ú¦P级¦X¬ù¡A¦ô³Ì°ª销°â31.2»õ¬ü¤¸¡C (·í®ÉDupilumab ¥«³õ»{¦P¥¼¨Ó³Ì°ª¥i销60»õ¬ü¤¸)
2.2020¦~¤¸¤ë ¦PMOAªº¨ÖÁʧé²{»ùÈ 29»õ¬ü¤¸. 2020/01 §¨Ó¨ÖÁÊDermira ¤½¥q
11»õ¬ü¤¸²{ª÷+ ¤ä¥Iù¤óROCHE Lebrikizumab¥þ²yAD¶}µoÅv,°Ó·~¾P°â¨ã¦³¨½µ{¸O·N¸q®É¤ä¥I2.1»õ¬ü¤¸¡A°£¶¡½è©ÊªÍ¯f¥H¥~ªº¾AÀ³¯gªº²b¾P°âÃB¹F¬Y¨Ç»ùȳ̰ª¹F¨ì10.25»õ¬ü¤¸,¦Xp¬ù12.35»õ¬ü¤¸,¥[¾P°â¤À¼í<= 10%.
§é²{Ȧô 11»õ¬ü¤¸+18»õ¬ü¤¸=29»õ¬ü¤¸,
3.2020/7/13
a.¦]Dupilumab ¥«³õ»{¦P°ª¾P°âÃB´£¤É¨ì110»õ¬ü¤¸¡C ASLAN004ÀH¥«³õÂX¤j¡A¥¼¨Ó·s°ê»Ú±ÂÅvÈ¨Ì¾Ú ³Ì°ª¾P°â¦ô¥i¹F60»õ¬ü¤¸
b¡D2020¦~¤¸¤ë§¨Ó¨ÖDermiraªº§é现»ù¡A¤w¹F29»õ¬ü¤¸¡C
LebriKiulmabªº¤T´Áý³Ý¡A2017¦~¸Ñª¼¥¢±Ñ¡CªÍ³¡C0PD¥ç¥¢±Ñ¡C
C¡D¨È·à¦³¦Pdupilumab ¸ô®|, ý³Ý/ªÍ³¡COPD¨â¤j¾AÀ³¯g¦¨¥\¤j¾÷·|¡C ¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X¡X ¥¼¨ÓªºASLAN004 ±ÂÅv¦X约±ø¥ó:¦ôp ±ÂÅvª÷30»õ¬ü¤¸+销°â¤À¼í¡]隠§t60»õ¬ü¤¸³Ì°ª¾P°â¡^ §é²{È45»õ¬ü¤¸¡C
¨È狮¥i¤À30»õ¬ü¤¸+2bÁ{§É»ùÈ4»õ¬ü¤¸¦@34e¬ü¤¸¡C CSL¥i¤À15»õ¬ü¤¸. -------------------------------------------------- Y¥¼¨Ó¨ÖÁʵo¥Í,¥i¯à¦X¬ù:
1. ¡X¡X¥Ø«e¤ä¥I¨È·à²{ª÷»ù30e¬ü¤¸¡þ¡X¡X¡XÀH®É¯àµo¥Í ¡X¡X©ÎY¦b2022 °µ§¹2b ADÁ{§É ¡Ï4e =34e ¬ü¤¸¡X¡X2022¦~¤U¥b¦~
2. ¡Ï©Ó¾á¤ä¥ICSL 2019¦~5¤ë31¤é±ÂÅv¦X¬ù±ø¥ó: ±ÂÅvª÷7.8»õ¬ü¤¸¡Ï5~10% ¾P°â¤À¼í
----¬Ý§¹¼v¤ù´Nª¾¹D
ASLAN004 MOA -¼v¤ù
aslanpharma.com/drug/aslan004/
¤£À´¬Ý¨ìÀ´,´N¬Oªø§ë°ò¥»¥\.¤@³q¥|Ãĺɳq! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥Í¬¡10151342 |
µoªí®É¶¡:2021/3/1 ¤U¤È 03:49:39
²Ä 3787 ½g¦^À³
|
¤Ñ©R¤j¡A½Ð±Ð¤@¤U¡A¬°¦ó004·|¤ñ¦X¤@ªº825±ÂÅv»ùÈÁÙ°ª©O¡H²£«~¦³¦ó¤£¦P¶Ü¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2021/3/1 ¤U¤È 01:53:31
²Ä 3786 ½g¦^À³
|
5.5X62,000¤dªÑ=3.4»õ¬ü¤¸ ¥«È¡AÄY«§C¦ô¨È·à±dªº»ùÈ.
¥i¾P°â60»õ¬ü¤¸ªº1b, ±ÂÅvª÷(«eª÷¡Ïùµ{ª÷)¬ù30»õ¬ü¤¸¡A ¦©°£CSL7.8»õ¬ü¤¸, ¨È·à¤À±o¦³22.2»õ¬ü¤¸¬O¦X¤@FB825 5.3»õ¬ü¤¸ªº¥|¿¦h¡]22.2/5.3=4.18),
¦X¤@«Å¥¬±ÂÅvFB825µ¹leo «á,¦b¥xÆW¤jº¦25»õ¬ü¤¸(30-233)¡C¡]FB825ªº¼Æ¾Ú¶È12¦ì)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2021/3/1 ¤U¤È 01:29:03
²Ä 3785 ½g¦^À³
|
°ê¥~¤ÀªR®v¥h¦~µ¹·à¤lªº¥Ø¼Ð»ù5.5¬ü¤¸¤w¦b¤W¶g´X¥G¹F¦¨ ¤£ª¾¦³¨S¦³¤ÀªR®v¦A½Õ°ª·à¤l¥¼¨Ó¥Ø¼Ð»ù? ·Pı¦pªG¦³·s³ø§i¡A´N·|¦A±À¤É·à¤lªÑ»ù°Ê¯à |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2021/3/1 ¤W¤È 11:02:36
²Ä 3784 ½g¦^À³
|
www.drskin.com.tw/Articles.asp?BlockName=ArtView&AC1_ID=5&AT_ID=168 ¦¨¤Hªº²§¦ì©Ê¥Ö½§ª¢¥i¯à¬O§½³¡¥X²{¡A¤]¥i¥H¬O¥þ¨¥X²{ª¬ªp¡A[³\¦h¬OIge¼ÆÈ¥¿±`]----«DÄÝFB825¾A¥Î±wªÌ! |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 2801 ~ 2900 «h¦^ÂÐ >> |